Document:

<PAGE>

CONFIDENTIAL TREATMENT REQUESTED                                    EXHIBIT 10.1

CONFIDENTIAL TREATMENT REQUESTED:  PAGES WHERE CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED ARE MARKED "CONFIDENTIAL TREATMENT REQUESTED" AND APPROPRIATE
SECTIONS, WHERE TEXT HAS BEEN OMITTED, ARE NOTED WITH "[CONFIDENTIAL TREATMENT
REQUESTED]."  AN UNREDACTED VERSION OF THIS DOCUMENT HAS BEEN FILED SEPARATELY
WITH THE SECURITIES AND EXCHANGE COMMISSION.

                        LICENSE AND PURCHASE AGREEMENT

     This License and Purchase Agreement (the "Agreement") is entered into as of
March 1, 2000 (the "Effective Date"), by and between CardioDynamics
International Corporation ("Seller"), a California corporation, with its place
of business located at 6175 Nancy Ridge Drive, Suite 300, San Diego, California
92121 and Profiles In Health, Inc., a California corporation ("Buyer"), with its
place of business located at 11190 Warner Avenue, Suite 305, Fountain Valley,
California 92708.

                                   RECITALS

     A.   Seller has developed hemodynamic monitors and accessory electrodes
capable of accurately monitoring the hemodynamic status of patients.

     B.   Buyer is in the business of providing healthcare data and support to
the healthcare industry for a range of disease states, infection control, and
exposure management needs (the "Monitoring Services").

     C.   Buyer desires to purchase from Seller, and Seller desires to develop
and sell to Buyer, certain products for use by Buyer in connection with the
Monitoring Services, all as more particularly described below.

     NOW, THEREFORE, in consideration of the premises, and the mutual covenants,
agreements, representations and warranties hereinafter set forth, the parties
hereto, intending to be legally bound, hereby agree as follows:

1.   PRODUCT

     (a)  Description. Seller shall sell to Buyer Seller's hemodynamic monitors
          -----------
("Monitors"), electrodes and Product Documentation, all as such products
(collectively, the "Products") are described in that certain letter dated the
Effective Date from Seller's counsel, Pillsbury Madison & Sutro LLP, to Buyer's
counsel, Gibson, Dunn & Crutcher LLP (the "Letter"). The first forty (40)
Monitors sold to Buyer shall be "Phase 1" Monitors (as described in Exhibit A of
the Letter). All additional Monitors sold to Buyer shall be either "Phase 2"
Monitors (as described in Exhibit A of the Letter) or "Phase 3" Monitors,
                          ---------
subject to the terms and conditions set forth herein.

     (b)  Development.
          -----------

               (i)  Phase 2 Monitors.  Buyer and Seller shall work together to
                    ----------------
     jointly develop the "Phase 2" Monitors in accordance with the parameters
     described in this Section 1(b) (the "Development Program"), including,
                       ------------
     without limitation, preparation of mutually agreed upon specifications for
     the Products (the "Specifications"). Seller shall bear all expenses related
     to the Development Program and shall own all intellectual property created
     through the Development Program. Seller shall use commercially reasonable

                                      -1-
<PAGE>

     efforts to, and shall commit commercially reasonable resources and
     personnel necessary for, the development of the "Phase 2" Monitors in
     accordance with the time schedule described herein, provided that (i) the
     Specifications for "Phase 2" Monitors shall be completed within two (2)
     weeks of the execution hereof, (ii) Seller shall use commercially
     reasonable efforts to complete and obtain FDA clearance for sale of the
     "Phase 2" Monitors to Buyer within one hundred twenty (120) days of the
     date hereof, (iii) Buyer shall use commercially reasonable efforts to
     complete and obtain FDA clearance for sale of the Monitoring Services
     utilizing "Phase 2" Monitors to its customers within one hundred twenty
     (120) days of the date hereof and (iv) Seller and Buyer shall each provide
     the other with monthly status updates (or, more often as they are informed
     of relevant information) in respect of the FDA clearance process for "Phase
     2" Monitors or Monitoring Services, as the case may be.

               (ii)  Phase 3 Monitors. Upon Seller's request, Buyer shall work
                     ----------------
     with Seller to jointly develop the "Phase 3" Monitors in accordance with
     such parameters as may be mutually agreed upon by the parties, including,
     without limitation, preparation of mutually agreed upon Specifications.
     Seller shall bear all expenses related to and shall own all intellectual
     property created in respect of the development of "Phase 3" Monitors. The
     parties acknowledge that (A) notwithstanding Buyer's obligation to
     cooperate with Seller in the development of "Phase 3" Monitors, Seller
     shall have no obligation to develop any "Phase 3" Monitors and (B) the
     purchase price for all Monitors shipped to Buyer after the 1250/th/ Monitor
     shall be as set forth in Exhibit A attached hereto, regardless of whether
                              ---------
     it is a "Phase 2" or "Phase 3" Monitor.  In the event "Phase 3" Monitors
     are developed, Seller shall use commercially reasonable efforts to complete
     and obtain FDA clearance for sale of the "Phase 3" Monitors to Buyer and
     Buyer shall use commercially reasonable efforts to complete and obtain FDA
     clearance for sale of the Monitoring Services utilizing "Phase 3" Monitors
     to its customers.

     (c)  Acceptance Testing.  The "Phase 2" and "Phase 3" Monitors shall be
          ------------------
submitted to Buyer for acceptance testing. A representative of Seller will
jointly perform acceptance testing with Buyer. If the tested Monitor does not
meet the Specifications, Seller shall promptly correct and re-submit the Monitor
for additional testing. When the Monitor performs in accordance with the
Specifications and Buyer has acknowledged such performance in writing, such
phase of Monitor shall be shipped to Buyer in lieu of the previous phase of
Monitor commencing with respect to all future POs (as defined below) received
following Buyer's acceptance and FDA clearance of such phase of Monitor. If any
phase of Monitor fails to meet the Specifications within thirty (30) days of the
initial submission of such phase to Buyer for acceptance, Buyer shall have the
right to either terminate this Agreement or to utilize other suppliers of
Monitors until such time as such phase of Monitor meets such Specifications, at
Buyer's option, and if the failure relates to "Phase 3" Monitors and Buyer
elects to terminate, Buyer shall have the right to require Seller to ship "Phase
2" Monitors until an adequate substitute for Seller's Monitors can be found. In
the event of Buyer's election to terminate, Buyer shall be obligated to purchase
only those Monitors for which it has already provided Purchase Commitments (as
defined below) to Seller, plus those "Phase 2" Monitors for which Buyer submits
Purchase Commitments from the date of Buyer's election to terminate the
Agreement through the effective date of such termination (i.e., the date upon
                                                          ----
which Buyer notifies Seller that Buyer has found an adequate substitute for
Seller's Monitors).

                                      -2-
<PAGE>

     (d)  Quality Assurance.  All Products purchased by Buyer shall be inspected
          -----------------
and tested prior to shipping in accordance with ISO 9001 and good manufacturing
procedures.

     (e)  Buyer Software.  Seller shall install Buyer's then applicable software
          --------------
on all Product prior to shipping at no additional charge to Buyer. Buyer shall
provide to Seller the Buyer software prior to placement of Buyer's first PO and
shall from time to time provide Seller with updates and upgrades to such Buyer
software at least ten (10) business days prior to installation; provided,
                                                                --------
however, that Seller's obligation to install such updates and upgrade shall be
-------
subject to Buyer's receipt of any required FDA clearance or other regulatory
approvals. So long as the Products conform to the Specifications, Buyer is
solely responsible for the performance of its software with the Products, and
Seller shall have no responsibility with respect to the failure of Buyer's
software to perform with the Products. Seller shall have no right to use or
distribute the Buyer software other than in connection with delivery of Products
to Buyer and shall treat the Buyer software as Buyer's Proprietary Information.
Any other use, reproduction, sale, promotion, reverse-engineering, decompiling
or distribution by Seller or its agents of any Buyer software is strictly
prohibited, and Seller shall indemnify Buyer for any breach of this restriction
in accordance with the provisions of Section 13

     (f)  Product Changes.  Seller reserves the right to improve, modify, alter
          ---------------
or adapt the Products, but will not make any changes affecting the form, fit or
function of the Products or the operation of Buyer's software with the Products
without the prior written approval of Buyer. Buyer reserves the right to suggest
improvements or other modifications to the Products and Seller shall be required
to implement the suggested improvements or other modifications if Buyer and
Seller mutually agree upon the specifications and development schedule for
implementation of such changes and Buyer pays all costs associated with such
changes.

2.   ORDERS

     (a)  Purchase Orders.  Products can only be purchased through issuance of a
          ---------------
purchase order ("PO") to Seller. Each PO issued under this Agreement shall be
deemed to be a separate agreement and shall incorporate by this reference all of
the terms and conditions of this Agreement. Each PO shall contain only the
following information:

               (i)    the date of the PO and the PO number;

               (ii)   the description of the specific Products ordered and the
     quantity ordered;

               (iii)  the purchase price;

               (iv)   the location to which the ordered Products are to be
     delivered; and

               (v)    the shipment date for the ordered Products.

     (b)  Controlling Terms.  The preprinted or handwritten terms and
          -----------------
conditions, or any other terms or conditions inconsistent with the terms of this
Agreement, appearing in or on the reverse side of a PO or in or on Seller's
acknowledgment, invoice or shipment form shall not apply to or become part of
the PO regardless of any statement to the contrary contained in such form or
preprinted terms.

                                      -3-
<PAGE>

     (c)  Forecasts.  Buyer shall submit to Seller by the second week of each
          ---------
month non-binding rolling 180-day monthly forecasts of the Products likely to be
purchased by Buyer for the 180-day period beginning on the first day of the
month immediately following the date on which such forecast is provided.

     (d)  Purchase Commitments.  Buyer shall submit to Seller on or before the
          --------------------
first day of each month binding purchase commitments ("Purchase Commitments")
for Products to be purchased by Buyer over the next 30, 60 and 90 days. Absent
Seller's consent, which may not be unreasonably withheld, Buyer may not vary its
POs with respect to the Purchase Commitment for the current month, and may vary
its POs with respect to Purchase Commitments for the following (i) sixty (60)
days by no more than five percent (5%) and (ii) ninety (90) days by more than
ten percent (10%). Purchase Commitments for any month shall not exceed one
hundred fifty percent (150%) of the most current forecast for such month, unless
otherwise expressly agreed upon in writing by the parties. If Buyer fails to
submit POs for Products in accordance with this Section 2(d) and is not excused
by Section 18(g) (Force Majeure), Buyer shall (i) remain liable for payment in
full of the Purchase Commitments and (ii) pay a penalty of five percent (5%) on
the Products not purchased, in addition to the amounts due with respect to
Purchase Commitments.

     (e)  Lead Time.  Buyer will submit POs to Seller with a lead time of two
          ---------
(2) business days prior to the requested shipment date. Buyer will contact
Seller if Seller has not provided an acknowledgement of a PO to Buyer within
twenty-four (24) hours of Buyer's submission.

     (f)  Lot Size.  No minimum amount of Product must be ordered on any
          --------
particular PO. POs received during any five (5) consecutive business days may
not contain orders for an aggregate of more than one-half (1/2) of the Purchase
Commitment for the next thirty (30) day period.

     (g)  Rescheduling/Cancellation.  Buyer may postpone, redirect the shipment
          -------------------------
of, or cancel any PO by delivering written notice of rescheduling to Seller,
however, Buyer shall not be relieved of its responsibility under this Agreement
to pay for all Purchase Commitments (including any penalties pursuant to Section
                                                                         -------
2(d).
----

     (h)  Shipment.Seller shall ship the ordered Products to the ship-to address
          --------
specified in the PO no later than (A) two (2) business days following receipt of
the completed PO for POs received before 2:00 p.m. and (B) three (3) business
days following receipt of the completed PO for POs received after 2:00 p.m.,
unless such PO designates a later date for shipment. Shipment is FOB Seller's
point of manufacture. Unless Buyer designates a carrier in the PO who agrees to
the shipment date, Seller shall select a commercially reasonable carrier.

     (i)  Late Shipments.  If Seller fails to ship any Products in accordance
          --------------
with Section 2(h) and is not excused by Section 18(g) (Force Majeure), Buyer
     ------------                       -------------
shall receive a discount of five percent (5%) on the applicable PO.

                                      -4-
<PAGE>

                                                CONFIDENTIAL TREATMENT REQUESTED

3.   MINIMUM PURCHASE AMOUNTS

     Buyer shall purchase Products in the annual minimum quantities ("Annual
Quotas") as described in the table below; provided, however, that if Seller
                                          --------  -------
fails to fill a PO in accordance with the time parameters established in Section
                                                                         -------
2(h), the Annual Quota applicable to such period shall be reduced by an amount
----
equal to the quantity of Product listed in such PO.

<TABLE>
<CAPTION>
---------------------------------------------------------------------------------------------------------------------
[CONFIDENTIAL TREATMENT REQUESTED]       Monitors                              Electrodes
---------------------------------------------------------------------------------------------------------------------
<S>                                      <C>                                   <C>
  [CONFIDENTIAL TREATMENT REQUESTED]     [CONFIDENTIAL TREATMENT REQUESTED]    [CONFIDENTIAL TREATMENT REQUESTED]
---------------------------------------------------------------------------------------------------------------------
  [CONFIDENTIAL TREATMENT REQUESTED]     [CONFIDENTIAL TREATMENT REQUESTED]    [CONFIDENTIAL TREATMENT REQUESTED]
---------------------------------------------------------------------------------------------------------------------
  [CONFIDENTIAL TREATMENT REQUESTED]     [CONFIDENTIAL TREATMENT REQUESTED]    [CONFIDENTIAL TREATMENT REQUESTED]
---------------------------------------------------------------------------------------------------------------------
  [CONFIDENTIAL TREATMENT REQUESTED]     [CONFIDENTIAL TREATMENT REQUESTED]    [CONFIDENTIAL TREATMENT REQUESTED]
---------------------------------------------------------------------------------------------------------------------
  [CONFIDENTIAL TREATMENT REQUESTED]     [CONFIDENTIAL TREATMENT REQUESTED]    [CONFIDENTIAL TREATMENT REQUESTED]
---------------------------------------------------------------------------------------------------------------------
</TABLE>

     Annual Quotas for any renewal or extension of this Agreement beyond five
years shall be agreed upon by Buyer and Seller in writing no later than sixty
(60) days prior to the end of the initial term.

     Notwithstanding anything to the contrary contained in this Agreement, Buyer
shall have the right, in addition to Buyer's right to terminate this Agreement,
to purchase from third parties products similar to the Products (the "Substitute
Products") during the following periods:

          (i)   commencing at any time following Buyer's receipt of notice from
     Seller of Seller's inability to ship any "Phase 1" or "Phase 2" Monitors
     (where such inability is not due to action or failure to act on the part of
     Buyer) and ending upon such date as Seller provides notice to Buyer of its
     ability to immediately ship "Phase 1" or "Phase 2" Monitors; and

          (ii)  commencing on the date that Buyer receives notice that the FDA
     or other applicable regulatory agency has stopped the sale of the Products
     or the provision of Monitoring Services (where such action is not related
     to Buyer's software or services) and ending on such date as Buyer receives
     notice that such restriction on the sale of Products or provision of
     Monitoring Services has been removed.

     In the event Buyer elects to exercise its rights hereunder in lieu of
terminating this Agreement, all Substitute Products purchased by Buyer shall be
applied against any outstanding Purchase Commitments and applicable Annual
Quotas (including for purposes of determining any volume discounts).

4.   PRODUCT PRICING

     (a)  Prices.  The prices for the Products, including volume purchase
          ------
discounts, appear in Exhibit A attached hereto. Prices include packaging in
                     ---------
accordance with Seller's standard

                                      -5-
<PAGE>

                                                CONFIDENTIAL TREATMENT REQUESTED

practice.  All prices are FOB Seller's point of manufacture and do not include
freight and handling charges or Taxes (as defined below).

     (b)  Taxes.  The Product prices are exclusive of any U.S. federal, state,
          -----
local or other taxes, duties or excises or similar taxes applicable to the sale
of the Products ("Tax" or "Taxes"), other than taxes based on Seller's net
income. If Seller pays or is assessed any Taxes, Seller shall itemize such Taxes
on the corresponding acknowledgment. Buyer shall reimburse Seller for any and
all such Taxes. Seller shall not collect and Buyer shall have no obligation to
reimburse Seller for Taxes to the extent that Buyer can deliver a valid tax
exemption certificate from the appropriate tax authority. The party paying a Tax
shall have the right to any Tax refund paid due to any overpayment of such Tax.

     (c)  Price Changes.  Except as otherwise set forth herein, the prices
          -------------
listed on Exhibit A for the Products are firm for the quantities stated.  No
          ---------
failure by Buyer to meet the Annual Quota for any particular year will affect
the volume purchase discounts described on Exhibit A (i.e., if Buyer fails to
                                           ---------
meet the Annual Quota obligation to purchase [CONFIDENTIAL TREATMENT REQUESTED]
monitors in [CONFIDENTIAL TREATMENT REQUESTED], when Buyer purchases monitor
[CONFIDENTIAL TREATMENT REQUESTED] it will receive the volume discount price
listed on Exhibit A of [CONFIDENTIAL TREATMENT REQUESTED]).
          ---------

     (d)  Payment Terms.  Payment terms are net sixty (60) days from the date of
          -------------
invoice payable in U.S. dollars; provided, however, that a portion of the
                                 --------  -------
payment otherwise due will be deferred as described in Section 4(e) below.
                                                       ------------
Seller's shipping invoice will state the purchase price, freight and handling
costs, any applicable Taxes and any other agreed-upon charges for the ordered
Product. All prices referenced are quoted in U.S. dollars. Payments shall be
made as directed on Seller's shipping invoice. Seller's performance is
specifically contingent on Buyers timely payments. Seller reserves the right to
suspend performance under this Agreement or any PO and to exercise any or all
remedies available to Seller if Buyer fails to make timely payments. The failure
of Seller to suspend performance in a particular instance, or the failure of
Seller to exercise any and all available remedies at a particular time, shall
not be deemed a waiver of Seller's rights.

     (e)  Deferred Purchase Price/Convertible Secured Promissory Note;.
          ------------------------------------------------------------

               (i)   Convertible Secured Promissory Note. Seller will accept
                     -----------------------------------
     Buyer's convertible secured promissory note and security agreement (the
     "Note"), substantially in the form attached hereto as Exhibit B, evidencing
                                                           ---------
     Buyer's obligation to pay Seller the deferred portion of the purchase price
     for Products purchased within the first two (2) years of the Term, as
     provided in Exhibit A (the "Deferred Amounts"); provided, however, that if
                 ---------                           --------  -------
     Buyer has not provided satisfactory evidence to Seller that it has received
     equity funding from the date of this Agreement in an amount equal to at
     least $1.5 Million at the time that the 40/th/ "Phase 1" Monitor ships,
     then Seller shall not be required to defer a portion of the purchase price
     for any Phase 2 Monitors until such time as Buyer provides such evidence.
     Buyer shall deliver the Note to Seller at the time Buyer delivers payment
     in connection with its first order of Products.

               (ii)  Security Interest.  Buyer shall grant to Seller a security
                     -----------------
     interest in certain assets of Buyer pursuant to the terms and conditions
     set forth in the Note. The security interest will be released upon payment
     in full of all outstanding sums owed under the

                                      -6-
<PAGE>

     Note. Buyer consents to Seller executing, on Buyer's behalf and in Buyer's
     name, or Buyer will execute as required by Seller, financing statements,
     UCC forms, and other instruments to perfect Seller's security interest
     under the Note.

5.   RETURN PROCEDURE

     (a)  RMA Requirement.  Before returning any Product for repair or
          ---------------
replacement, Buyer must first contact Seller and obtain a Return Material
Authorization ("RMA") number. The following information must be supplied to
Seller in order to obtain an RMA number:

               (i)    Shipment and delivery dates;

               (ii)   Description of the problem;

               (iii)  Offsetting no-charge PO for replacement of Product (if
     approved by Seller);

               (iv)   Description of the products;

               (v)    Serial number;

               (vi)   Part number;

               (vii)  Lot number and

               (viii) Date code.

     (b)  Return Procedure.  Upon receipt of the RMA number from Seller, Buyer
          ----------------
will return the Product to Seller. The RMA number must be referenced on all
correspondence regarding the returned Product, as well as on the shipping
containers or package and all shipping documents. Product returned without RMA
numbers or authorization will not be accepted. All returned Product must be
properly and commercially reasonably packaged. Seller is not responsible for
damage to the Product en route to Seller incurred in shipment or due to
inadequate or improper packaging. Buyer retains title to the Product returned
for repair.

     (c)  Repair or Replacement.  If Seller verifies the claimed defect or
          ---------------------
failure and the Product is under warranty Seller will promptly repair or replace
the defective Product at its expense or refund the purchase price paid by Buyer
for such Product, at Seller's option. Seller shall keep on site a sufficient
repair/warranty inventory to allow for the swap out and prompt replacement of
any Product which malfunctions in the hands of Buyer or Buyer's customers;
provided, however, that with respect to "Phase 1" Monitors, Seller shall have
--------  -------
the option of providing the swap out and replacement of any such Monitors with
either "Phase 1" Monitors or "Phase 2" Monitors, at Seller's expense.

     (d)  Shipping Cost Allocation.  Transportation charges on any Product
          ------------------------
returned from Buyer shall be at Buyer's expense. Any Product returned from
Seller to Buyer shall be at Seller's expense.

                                      -7-
<PAGE>

6.   TRAINING AND TECHNICAL SUPPORT

     (a)  Training.  Seller shall provide Buyer with up to sixteen (16) hours of
          --------
"train the trainers" training in a maximum of two (2) contiguous daily sessions
for up to five (5) personnel of Buyer with respect to the use of each of the
"Phase 1", "Phase 2" and "Phase 3" Monitors at locations specified by Seller.
Each party will bear its own expenses in connection with such training.

     (b)  Technical Support. Seller shall support Buyer's use of Products, by
          -----------------
providing technical support, testing and trouble shooting of Products at
Seller's expense. Buyer may access Seller's technical support staff, via
telephone or e-mail only, during such support staff's normal hours of operation
for ten (10) hours per quarter following delivery of the first "Phase 1"
monitor, twenty (20) hours per quarter following delivery of the first "Phase 2"
Monitor and thirty (30) hours per quarter following the delivery of the first
"Phase 3" Monitor. Buyer shall be charged in accordance with Seller's support
pricing structure, as such structure may be changed from time to time in
Seller's discretion, for access in excess of the above hours per quarter with
respect to any particular phase of Monitor.

7.   LICENSE, TRADEMARKS AND TRADENAMES

     (a)  License.  Seller grants a non-exclusive, worldwide, nontransferable
          -------
(except for Product sales made in accordance with Section 12(b)) license to
Buyer to utilize with respect to Buyer's provision of Monitoring Services in
accordance with the terms of this Agreement, without right to sublicense or
assign except in conjunction with the provision of Monitoring Services to
Buyer's customers, one copy of all Seller software associated with the Products
("Product Software") and all Product Documentation (as defined on Exhibit A of
                                                                  ---------
the Letter) per Monitor or electrode purchased by Buyer, including all updates
or upgrades thereto. Any other use, reproduction, sale, promotion, reverse-
engineering, decompiling or distribution by Buyer, its agents or customers of
any Product, Product Software or Product Documentation is strictly prohibited,
and Buyer shall indemnify Seller for any breach of this restriction in
accordance with the provisions of Section 13.

     (b)  Marks.  Each party shall not use the other party's name or any other
          -----
trademark or trade name used or claimed by the other party (all of which names
or marks shall hereinafter be referred to as the "Marks") in connection with any
business conducted by such party. Each party agrees that it will not use,
without the other party's prior written consent, any mark which is likely to be
similar to or confused with the Marks belonging to the other party.

     (c)  Publicity.  Each party hereto must approve, in advance in writing,
          ---------
such approval not to be unreasonably withheld, any advertising or promotional
literature or announcement to the press by the other party regarding its
relationship with the other party or otherwise utilizing the other party's name.

     (d)  Resale and Goodwill.  All Products will be utilized and all Monitoring
          -------------------
Services will be provided under Buyer's trademarks and all goodwill associated
with such Monitoring Services shall belong to Buyer.

                                      -8-
<PAGE>

     (e)  Bug Fixes.  Seller shall, at Seller's expense, (i) promptly correct
          ---------
significant "bugs," and (ii) correct any other "bugs" under a mutually agreed
upon development and upgrade schedule.

8.   REPRESENTATIONS, WARRANTIES AND COVENANTS OF SELLER

     Seller represents, warrants and covenants to Buyer as follows:

     (a)  Seller has all requisite corporate power and authority to enter into
this Agreement and to consummate the transactions contemplated hereby and to
perform its obligations hereunder. Seller is, and will be at all relevant times,
the lawful owner of its Proprietary Rights and the Products and has and will
have the right to license, sell and transfer them to Buyer as contemplated
herein, free and clear of all liens, mortgages, pledges, security interests,
restrictions, prior assignments, encumbrances and claims of any kind. The
execution, delivery, and performance by Seller of this Agreement and the
consummation of the transactions contemplated hereby do not and will not result
in the violation of any agreement, instrument, or contract to which Seller is a
party or by which it is bound or of any federal or state judgment, order, writ,
decree, statute, rule, regulation or restriction applicable to Seller, and do
not and will not result in a material conflict with or constitute, with or
without the passage of time or giving of notice, either a material default under
any such provision or an event that results in the creation of any material
lien, charge, or encumbrance upon any Products or the suspension, revocation,
impairment, forfeiture, or nonrenewal of any material permit, license,
authorization, or approval applicable to the Products. Except as set forth in
that certain letter dated January 12, 2000 from Bo Sramek (the "Sramek Letter"),
no third party has asserted, or threatened to assert, a claim that it owns all
or any part of Seller's Proprietary Rights or the Products.

     (b)  Seller owns or possesses sufficient legal rights to all patents,
trademarks, service marks, trade names, copyrights, trade secrets, licenses,
information, and proprietary rights and processes necessary for its business as
now conducted without any conflict with, or infringement of the rights of,
others.  There are no outstanding options, licenses, or agreements of any kind
relating to the Monitors.  Seller has not received any communications alleging
that it has violated or, by selling Products as contemplated by this Agreement,
would violate any of the patents, trademarks, service marks, trade names,
copyrights, trade secrets, licenses, information or other proprietary rights or
processes of any other person or entity, except for the Sramek Letter.

     (c)  Neither this Agreement (or any term hereof) nor the performance of or
exercise of rights under this Agreement, is restricted by, contrary to, in
conflict with, ineffective under, requires registration or approval or tax
withholding under, or affects Seller's Proprietary Rights (or the duration
thereof) under, or will require any termination payment or compulsory licensing
under, any applicable law or regulation.

     (d)  Except for the FDA clearances described in Section 10(a), Seller has
                                                     -------------
all franchises, permits, licenses, and any similar authority necessary for
Seller to consummate the transactions contemplated hereby. Seller is not in
default in any material respect under any of such franchises, permits, licenses
or other similar authority. Seller shall at all times, at Seller's sole expense,
materially comply with all applicable laws and regulations relating to Seller's
activities.

                                      -9-
<PAGE>

     (e)  Seller shall promptly notify Buyer of any malfunction or deterioration
in the performance of Seller's Products of which Seller becomes aware that might
lead to or may have led to the death or serious injury of a patient or user or
any actual or potential government action relevant to a Product or the
Monitoring Services, to the extent such incidents must be reported to the FDA
under applicable federal law. Seller has supplied, or will supply when shipping
any Product, all of Seller's safety information and operating instructions
relating to the Products.

     (f)  Except for the FDA clearances described in Section 10(a), no consent,
                                                     -------------
approval, qualification, order or authorization of, or filing with, any local,
state, or federal governmental authority is required on the part of Seller in
connection with Seller's performance of this Agreement.

     (g)  Seller is not bound by any agreement that affects Buyer's right to
purchase the Products and provide Monitoring Services in accordance with the
terms of this Agreement.

     (h)  Except with respect to the Sramek Letter, there is no action, suit,
proceeding, or investigation pending or currently threatened against Seller that
questions the validity of this Agreement or the ownership of the Proprietary
Rights of Seller or of the Products.  Seller is not a party to or named in or
subject to any order, writ, injunction, judgment, or decree of any court,
government agency, or instrumentality.

     (i)  Seller has in full force and effect fire and casualty insurance
policies, with extended coverage, sufficient in amount (subject to reasonable
deductibles) to allow it to replace any of its properties that might be damaged
or destroyed. Seller has in full force and effect products liability insurance
in amounts customary for companies similarly situated.

9.   REPRESENTATIONS, WARRANTIES AND COVENANTS OF BUYER

     Buyer represents, warrants and covenants to Seller as follows:

     (a)  Buyer has all requisite corporate power and authority to enter into
this Agreement and to consummate the transactions contemplated hereby and to
perform its obligations hereunder. Buyer is the lawful owner of its Proprietary
Rights and the Monitoring Services and has the right to utilize them as
contemplated herein, free and clear of all liens, mortgages, pledges, security
interests, restrictions, prior assignments, encumbrances and claims of any kind.
The execution, delivery, and performance by Buyer of this Agreement and the
consummation of the transactions contemplated hereby do not and will not result
in the violation of any agreement, instrument, or contract to which Buyer is a
party or by which it is bound or of any federal or state judgment, order, writ,
decree, statute, rule, regulation or restriction applicable to Buyer, and do not
and will not result in a material conflict with or constitute, with or without
the passage of time or giving of notice, either a material default under any
such provision or an event that results in the creation of any material lien,
charge, or encumbrance upon Buyer's assets or the suspension, revocation,
impairment, forfeiture, or nonrenewal of any material permit, license,
authorization, or approval applicable to Buyer. No third party has asserted, or
threatened to assert, a claim that it owns all or any part of Buyer's
Proprietary Rights or the Monitoring Services.

                                      -10-
<PAGE>

     (b)  Buyer owns or possesses sufficient legal rights to all patents,
trademarks, service marks, trade names, copyrights, trade secrets, licenses,
information, and proprietary rights and processes necessary for its business as
now conducted without any conflict with, or infringement of the rights of,
others. There are no outstanding options, licenses, or agreements of any kind
relating to the Monitoring Services. Buyer has not received any communications
alleging that it has violated or, by providing Monitoring Services, would
violate any of the patents, trademarks, service marks, trade names, copyrights,
trade secrets, or other proprietary rights or processes of any other person or
entity.

     (c)  Neither this Agreement (or any term hereof) nor the performance of or
exercise of rights under this Agreement, is restricted by, contrary to, in
conflict with, ineffective under, requires registration or approval or tax
withholding under, or affects Buyer's Proprietary Rights (or the duration
thereof) under, or will require any termination payment or compulsory licensing
under, any applicable law or regulation.

     (d)  Except for the FDA clearances described in Section 10(a), Buyer has
                                                     -------------
all franchises, permits, licenses, and any similar authority necessary for Buyer
to consummate the transactions contemplated hereby. Buyer is not in default in
any material respect under any of such franchises, permits, licenses or other
similar authority. Buyer shall at all times, at Buyer's sole expense, materially
comply with all applicable laws and regulations relating to Buyer's activities.

     (e)  Buyer shall promptly notify Seller of any malfunction or deterioration
in the performance of Seller's Products or Monitoring Services of which Buyer
becomes aware that might lead to or may have led to the death or serious injury
of a patient or user or any actual or potential government action relevant to a
Product or the Monitoring Services, to the extent such incidents must be
reported to the FDA under applicable federal law. If and to the extent requested
by Seller in writing and if required by the FDA, Buyer will suspend use of such
Product in the provision of Monitoring Services.

     (f)  Except for the FDA clearances described in Section 10(a), no consent,
                                                     -------------
approval, qualification, order or authorization of, or filing with, any local,
state, or federal governmental authority is required on the part of Buyer in
connection with Buyer's performance of this Agreement.

     (g)  There is no action, suit, proceeding, or investigation pending or
currently threatened against Buyer that questions the validity of this Agreement
or the ownership of the Proprietary Rights of Buyer. Buyer is not a party to or
named in or subject to any order, writ, injunction, judgment, or decree of any
court, government agency, or instrumentality.

     (h)  Buyer has in full force and effect fire and casualty insurance
policies, with extended coverage, sufficient in amount (subject to reasonable
deductibles) to allow it to replace any of its properties that might be damaged
or destroyed. Buyer has in full force and effect products liability insurance in
amounts customary for companies similarly situated.

                                      -11-
<PAGE>

     (i)  Buyer shall use reasonable commercial efforts to successfully market
Monitoring Services (including training and other support) on a continuing basis
and shall comply with good business practices relevant to this Agreement or the
subject matter hereof.

     (j)  Buyer shall report on a quarterly basis the names and addresses of
customers who receive Monitoring Services utilizing the Products and fully
cooperate in any decision by Seller to recall, retrieve and/or replace any
Product; provided, however, that Seller may utilize such names and addresses
         --------  -------
solely to comply with regulatory requirements and shall be prohibited from
utilizing such names and addresses for any commercial purpose.

     (k)  Buyer hereby grants to Seller a limited right to access the Data (as
such term is defined below) on terms deemed acceptable to Buyer for the sole
purpose of improving and refining the Products and Seller's software; provided,
                                                                      --------
however, that Buyer shall not be obligated to allow Seller access to any such
-------
Data if to do so would constitute a violation of any law or regulation.
Notwithstanding the limited access right described above, Seller hereby
acknowledges it has no ownership rights in or to the Data, that the Data is the
sole property of Buyer, and that Seller may not use or otherwise reveal the Data
for any purpose other than that of improving and refining the Products and
Seller's software. All expenses associated with collecting and providing the
Data to Seller shall be borne by Seller. For purposes hereof, "Data" means the
impedance waveform files generated through use of the Products.

     (l)  Buyer shall keep Seller informed as to any problems or material
customer complaints encountered with the Products and any resolutions arrived at
for those problems, and communicate promptly to Seller any and all
modifications, design changes or improvements of the Products suggested by any
customer, employee or agent. Buyer further agrees that Seller shall have any and
all right, title and interest in and to any such suggested modifications, design
changes or improvements of the Products, without the payment of any additional
consideration therefore either to Buyer, or its employees, agents or customers.
Buyer will also promptly notify Seller of any infringement of any trademarks or
other proprietary rights relating to the Products.

     (m)  Buyer will make no claims with respect to the capabilities of the
Products other than those stated in the Seller's approved labeling or marketing
literature.

10.  COMPLIANCE WITH UNITED STATES LAWS

     (a)  Regulatory Approvals. Except as otherwise set forth in this Section 10
          --------------------                                        ----------
or in Section 1(b), (i) Seller shall be responsible for identifying and
      ------------
obtaining, at Seller's sole cost, all regulatory approvals which are required in
the United States for the development, manufacture or sale of the Products and
(ii) Buyer shall not be obligated to order any Products until such time as
Seller has received FDA approval for the sale of the Products. The parties agree
that "Phase 1" Monitors shall be shipped as a custom prescription device and
that Buyer will provide Seller with a letter from a physician meeting the
requirements necessary to exempt the sale of "Phase 1" Monitors from FDA pre-
market clearance requirements (510(K)). Buyer shall be responsible for
identifying and obtaining, at Buyer's sole cost, all regulatory approvals which
are required in the United States for the provision of Monitoring Services.
Seller shall cooperate and provide Buyer with reasonable assistance in obtaining
such approvals, provided Buyer reimburses Seller for its costs in providing such
assistance.

                                      -12-
<PAGE>

     (b)  Exports.  Buyer acknowledges that the export from the United States of
          -------
the Products may be subject to regulation by the U.S. Export Administration Act
of 1979, as amended, and the rules and regulations promulgated thereunder, which
restrict exports and re-exports of any Products or direct product thereof. Buyer
agrees to comply with U.S. Export Administration Regulations as in effect from
time to time (including, without limitation, all record-keeping requirements
imposed thereunder), and will not re-export the Products in violation of such
Regulations. Without limitation of the foregoing, Buyer agrees to commit no act
which, directly or indirectly, would violate any United States law, regulation,
or treaty, or any other international treaty or agreement, relating to or
applicable to the export or re-export of the Products, to which the United
States adheres or with which the United States complies.

11.  CONFIDENTIALITY

     Each party hereto agrees that all inventions, know-how and ideas it obtains
from the other party hereto and all other business, technical and financial
information it obtains from the other party hereto are the confidential property
of the disclosing party ("Proprietary Information"). Except as expressly allowed
herein, each party hereto will hold in confidence and not use or disclose any
Proprietary Information of the other party hereto and shall similarly bind its
employees and consultants in writing. Information shall not be deemed to be
Proprietary Information if it: (i) is in the public domain at the time of
disclosure; (ii) becomes part of the public domain after disclosure in a manner
not involving breach of this Agreement; (iii) is in the possession of the
recipient at the time of disclosure as shown by its written records; (iv) is
lawfully disclosed to the recipient by a third party, free of any obligation of
confidentiality; or (v) is independently developed by the recipient's employees
or agents who had no contact with or access to the Proprietary Information.

     The receiving party will promptly report to the disclosing party any actual
or suspected violation of the terms of this Section 11, and will take all
                                            ----------
reasonable further steps requested by the disclosing party to prevent, control
or remedy any such violation. Each party shall upon termination of the Agreement
or the request of the other party hereto at any time, return to the disclosing
party all tangible manifestations of Proprietary Information received by the
disclosing party pursuant to this Agreement (and all copies and reproductions
thereof).

12.  COMPETITION

     (a)  Buyer shall at all times during the Term conduct its business in a
manner that reflects favorably on the Products and shall not, without Seller's
prior written consent, (i) purchase, lease, represent, promote, license or
otherwise utilize products that compete with the Products until such time as
Buyer has met its Annual Quota for the relevant period or (ii) resell, license
or lease the Products (either alone, or as a component of any other product or
system) to any third party, except in connection with the provision of
Monitoring Services or in connection with a permitted sale upon the terms and
conditions set forth in Section 12(b).
                        -------------

     (b)  Notwithstanding anything to the contrary contained in Section 12(a),
                                                                -------------
if at any time during the Term of this Agreement Buyer proposes to sell all or
substantially all of the Products then owned by Buyer pursuant to a bona fide
written offer from a third-party purchaser or third party purchasers in a single
transaction or series of related transactions, Buyer will make

                                      -13-
<PAGE>

a written offer to sell the Products to Seller for the same price and on the
same terms and conditions as those contained in the offer from the third party.
Seller may elect to accept Buyer's offer by written notice delivered to Buyer
within thirty (30) days after the offer is received. If Seller does not accept
Buyer's offer, Seller's right of first refusal will expire and Buyer may sell
the Products to the third-party purchaser or purchasers on the terms specified
in the original offer within ninety (90) days after the expiration of Seller's
right of refusal, although all other terms, covenants and conditions of this
Agreement will remain in effect. If Buyer does not sell the Products to the
third party or parties within the ninety (90) day period set forth in the
preceding sentence, this right of first refusal will remain in effect.

     (c)  Seller shall be prohibited during the Term from directly selling,
without Buyer's prior written consent, (i) Products meeting the specifications
set forth in Exhibit A of the Letter to healthcare professionals (whether as an
             ---------
individual or an entity) engaged in patient care or patient management, (ii)
Products which incorporate software which performs the same functions as the
Buyer software described in Exhibit B of the Letter, or (iii) services which
                            ---------
compete with any of the Buyer Services. For purposes hereof, the "Buyer
Services" shall means (i) the compilation, collation and combination of current
and historical, diagnostic, medication, laboratory and hemodynamic information
(except for research and marketing support purposes); (ii) the integration of
such data into individualized "patient profiles," (except for research and
marketing support purposes); (iii) the provision of "decision support" software
to suggest treatment protocol based on the individualized "patient profiles;"
(iv) the provision of consultative services to aid physicians in interpreting
patient data; (v) the establishment of local hub "profiling centers" where Buyer
Services may be performed; (vi) the provision of a national call center to serve
as a "hotline" for support of users of any Buyer Services (except Seller
technical support); and (vii) and the provision of infection control and blood
exposure management services.

13.  INDEMNIFICATION

     (a)  Intellectual Property. Seller agrees to defend, indemnify, reimburse
          ---------------------
and hold harmless Buyer and its Affiliates and their successors and assigns, and
the directors, officers, employees and agents of any of them from and against
any and all claims, losses, damages, liabilities, obligations, assessments,
penalties and interest, demands, actions and expenses, whether direct or
indirect, known or unknown, absolute or contingent (including, without
limitation, settlement costs and any legal and other expenses for investigating
or defending any actions or threatened actions) ("Losses") arising out of or in
connection with any claim for infringement of any United States intellectual
property rights ("Infringement Claim") as a result of the use or sale of the
Products. Buyer shall (i) give Seller prompt written notice of any such claim or
lawsuit and shall indemnify Seller for any Losses arising out of the failure to
Buyer to give prompt notice (provided that failure of Buyer to give prompt
notice to Seller shall not relieve Seller of its obligations hereunder), and
(ii) allow Seller to control, with the cooperation of Buyer, the defense of any
such claim and all related settlement negotiations. Seller shall have the option
of either defending or settling such a lawsuit. In the event that Buyer wishes
to participate in the defense of any such lawsuit, Seller shall allow Buyer to
participate at its own expense provided that Buyer does not take positions that
are inconsistent or prejudicial to Seller. Notwithstanding the above, Seller's
indemnification obligation under this Agreement for any Infringement Claim shall
be absolutely fulfilled if Seller, obtains a license for Buyer to continue

                                      -14-
<PAGE>

to use the Products, or replaces or modifies the Products so as to be
commercially and substantially equal, but not allegedly infringing.

     Seller has no obligations or liability under this section for any
Infringement Claim based on the use of Products or parts thereof when used in a
manner for which they were not designed or where modified by or for Buyer in a
manner to become allegedly infringing. Buyer acknowledges that Seller has no
responsibility for, or involvement in, designing Buyer's services or the, use,
method, manufacture, and provision of such services and Buyer further agrees
that the foregoing indemnification shall not apply and, moreover, shall be
reciprocally extended to Seller for any Infringement Claim which arises as a
result of the installation of Buyer's software.

     (b)  Product Liability. Seller agrees to defend, indemnify, reimburse and
          -----------------
hold Buyer harmless from and against any and all Losses arising out of or in
connection with the use of the Products ("Product Liability Claim") in
accordance with this Agreement. Buyer shall (i) give Seller prompt written
notice of any such claim or lawsuit and shall indemnify Seller for any Losses
arising out of the failure of Buyer to give prompt notice (provided that failure
of Buyer to give prompt notice to Seller shall not relieve Seller of its
obligations hereunder), and (ii) allow Seller to control, with the cooperation
of Buyer, the defense of any such claim and all related settlement negotiations.
Seller shall have the option of either defending or settling such a lawsuit. In
the event that Buyer wishes to participate in the defense of any such lawsuit,
Seller shall allow Buyer to participate at its own expense provided that Buyer
does not take positions that are inconsistent or prejudicial to Seller. The
parties shall be entitled to the benefits under, and proceeds of, all of the
other party's insurance policies, including product liability policies, and
shall be named as additional insureds thereto.

     Seller has no obligations or liability under this section for any Product
Liability Claim based on the use of Products or parts thereof when used in a
manner for which they were not designed or which arises as a result of the
installation of Buyer's software. Buyer acknowledges that Seller has no
responsibility for, or involvement in, designing Buyer's services or the, use,
method, manufacture, and provision of such services and Buyer further agrees
that the foregoing indemnification shall not apply and, moreover, shall be
reciprocally extended to Seller for any Product Liability Claim based on the use
of Products or parts thereof when used in a manner for which they were not
designed or which arises as a result of the installation of Buyer's software.

14.  WARRANTY AND DISCLAIMER

     Seller warrants that the Products and associated Seller's software will be
free from defects for one (1) year from date of shipment to Buyer. Products
purchased from Seller which do not comply with the warranty and are identified
to Seller during such period (with proof of the date of purchase) will be
repaired or replaced if promptly returned to Seller after such identification in
accordance with the return procedures described in Section 4. Significant
                                                   ---------
"bugs" and failures of the Products and associated Seller software to conform to
the Specifications will be promptly corrected at Seller's sole cost. SELLER
MAKES NO OTHER WARRANTIES WITH RESPECT TO THE PRODUCTS AND DISCLAIMS ALL OTHER
WARRANTIES, INCLUDING, WITHOUT LIMITATION, WARRANTIES OF MERCHANTABILITY AND
FITNESS FOR A PARTICULAR PURPOSE. The above warranty does not extend to any
Product if and to the extent that problems with the Product arise

                                      -15-
<PAGE>

as a result of the installation of Buyer's software, is not maintained to
Seller's maintenance recommendations, is operated, handled or stored in a manner
other than that specified by Seller, has its serial number removed or altered or
is treated with abuse, negligence or other improper treatment (including,
without limitation, use outside the recommended environment). Expendable items
such as electrodes, sensors, transducers, patient cables, etc., are also
warranted for ninety (90) days. Buyer's sole remedy with respect to any warranty
or defect is as stated above (unless Buyer purchases extended warranty coverage
from Seller at mutually agreed upon terms) and Buyer shall not otherwise have a
right of return. Buyer is responsible for satisfaction of its customers and will
be responsible for all claims, damages, settlements, expenses and attorneys fees
incurred by Seller with respect to Buyer's customers or their claims beyond
Seller's above warranty obligation to Buyer; provided, however, that Seller
                                             --------  -------
shall indemnify Buyer for all Losses incurred by Buyer arising from, or in
connection with, the use of the Products in a manner consistent with Seller's
operating specifications.

15.  RELATIONSHIP OF THE PARTIES

     The parties hereto expressly understand and agree that Buyer is an
independent contractor in the performance of each and every part of this
Agreement, is not an agent, and is solely responsible for all its employees and
agents and its labor costs and expenses arising in connection therewith and is
responsible for and will indemnify Seller from any and all claims, liabilities,
damages, debts, settlements, costs, attorneys' fees, expenses and liabilities of
any type whatsoever that may arise on account of Buyer's activities or
omissions, or those of its employees or agents, including without limitation,
providing unauthorized representations or warranties (or failing to effectively
disclaim all warranties and liabilities on behalf of Seller) to its customers or
breaching any term, representation or warranty of this Agreement. Buyer shall
have no power or authority to act for, bind or commit Seller. Seller shall have
no right to exercise any control whatsoever over the activities or operations of
Buyer.

16.  ASSIGNMENT

     This Agreement and the rights, interests or obligations hereunder may not
be transferred or assigned by either of the parties hereto (including, without
limitation, by merger or operation of law) without the prior written consent of
the other party, except that either party may transfer or assign its rights and
obligations under this Agreement in whole or in party to any affiliate or
affiliates of such party or any successor to all or substantially all of the
business or assets of such party (whether by stock or asset sale, merger or
operation of law).

17.  TERM AND TERMINATION

     (a) Term. Unless terminated earlier as provided herein, this Agreement
         ----
shall have an initial five (5) year term commencing upon the Effective Date,
with automatic annual renewal terms thereafter of one (1) year each (the
"Term"), unless (i) either party has provided the other party with notice of its
intent to terminate this Agreement at least sixty (60) days prior to the
beginning of the renewal term or (ii) the parties are unable to mutually agree
upon annual minimum quantities and pricing for such renewal term at least sixty
(60) days prior to the beginning of the renewal term. Buyer understands that
after the date specified above or earlier

                                      -16-
<PAGE>

termination, it shall have no right whatsoever to purchase Products regardless
of any undocumented continuation of the relationship with Seller.

     (b)  Termination.  This Agreement may be terminated by a party immediately
          -----------
by written notice upon the occurrence of any of the following events:

          (i)    If the other party ceases to do business, or otherwise
     terminates its business operations; or

          (ii)   If the other party shall fail to secure or renew any license,
     registration, permit, authorization or approval for the conduct of its
     business in the manner contemplated by this Agreement or if any such
     license, registration, permit, authorization or approval is revoked or
     suspended for a period of at least ten (10) days; or

          (iii)  If the other party breaches any provision of this Agreement and
     fails to substantially cure such breach within 30 days (10 days in the case
     of a failure to pay in accordance with the terms hereof) of written notice
     describing the breach; or

          (iv)   If the other party seeks protection under any bankruptcy,
     receivership, creditors arrangement or comparable proceeding, or if any
     such proceeding is instituted against the other party; or

          (v)    By Seller, if Buyer fails during any applicable 12-month period
     to purchase from Seller the Annual Quota; or

          (vi)   By Buyer, if Seller fails to deliver Products within the time
     frame specified in Section 2(h) for any four (4) consecutive POs; or
                        ------------

          (vii)  By Buyer, if FDA clearance is not received for the "Phase 2"
     Monitors within one hundred twenty (120) days of the Effective Date and
     such failure is not due to Buyer's software or services; or

          (viii) By Seller, if FDA clearance is not received for the Monitoring
     Services which utilize "Phase 2" Monitors within one hundred twenty (120)
     days of the Effective Date and such failure is not due to Seller's Products
     or software; or

          (ix)   By Buyer, if the FDA or other applicable regulatory agency
     stops the sale of the Products or the provision of Monitoring Services for
     a period of more than thirty (30) days and such action is not related to
     Buyer's software or services; or

          (x)    By Seller, if the FDA or other applicable regulatory agency
     stops the sale of Products or the provision of Monitoring Services for a
     period of more than thirty (30) days and such action is not related to
     Seller's software or Products; or

          (xi)   By Buyer if the parties are unable to reach agreement on the
     Specifications for "Phase 2" Monitors within two (2) weeks of the Effective
     Date, provided Buyer has exercised good faith efforts to reach agreement
     with Seller on such Specifications.

                                      -17-
<PAGE>

     (c) Consequences of Termination.
         ---------------------------

          (i)   Liability for Termination. Each party acknowledges and
                -------------------------
     understands that the rights of termination hereunder are absolute. Neither
     party shall incur any liability whatsoever for any damage, loss or expenses
     of any kind suffered or incurred by the other arising from or incident to
     any termination of this Agreement by such party which complies with the
     terms of the Agreement whether or not such party is aware of any such
     damage, loss or expenses.

          (ii)  Pending Orders. In the event of any termination, Seller will
                --------------
     fill all pending orders, unless termination was due to Buyers' breach.
     Seller reserves the right to refuse to fill any orders while any invoice is
     outstanding more than net 45 days.

          (iii)  Survival. In addition to any provisions that survive
                 --------
     termination according to their terms, the following sections shall survive
     termination of this Agreement: Sections 7, 8, 9, 10, 11, 13, 14, 17 and 18.

          (iv)   Other Remedies Preserved. Termination is not the sole remedy
                 ------------------------
     under this Agreement and, whether or not termination is effected, all other
     remedies will remain available, including, without limitation, (i) Seller's
     right to recover damages for the failure of Buyer to achieve all Product
     purchase quotas hereunder in the event of Buyer's breach of this Agreement
     and (ii) Buyer's right to terminate any Purchase Commitments and Annual
     Quotas in the event of Seller's breach of this Agreement.

          (v)    Manufacturing License.  If Seller becomes insolvent or enters
                 ---------------------
     bankruptcy proceedings, Seller hereby grants to Buyer an unrestricted,
     nonexclusive, worldwide license to use for the manufacture by or on behalf
     of Buyer of the Products all software (including source code), patents and
     other proprietary technology associated with the Products as may be
     necessary for the manufacture of the Products.  Seller shall cooperate
     fully with Buyer in the delivery of such license to Buyer and shall supply
     Buyer with (i) Seller's current bill of materials, (ii) the names and
     addresses of all suppliers and copies of all written agreements therewith,
     (iii) all applicable source code in such form as Buyer directs and (iv) all
     drawings, molds, know-how and other items necessary to manufacture the
     Products.  In the event Buyer exercises its right to use such license,
     Buyer shall pay Seller a royalty equal to seven percent (7%) of the
     applicable purchase price for the Product as set forth in Exhibit A within
                                                               ---------
     thirty (30) days following the month in which such Products were
     manufactured.

     (d) Duties of The Parties Upon Termination.
         --------------------------------------

          Without limiting the provisions of Section 17(c)(iv) hereunder, upon
                                             -----------------
     the termination of this Agreement for any reason whatsoever,

                 (A)  Buyer shall pay to Seller, in full by the due date owed
     for such amount, but in no event later than forty-five (45) days of such
     termination, all amounts owed to Seller (including amounts owed under the
     Note) for Purchase Commitments made prior to termination. Seller shall be
     entitled to set off and deduct from any payment due Buyer under this
     Agreement, any and all amounts due Seller from Buyer.

                                      -18-
<PAGE>

               (B)  Each party shall promptly return to the other party all
     Proprietary Information of the other party; provided, however, that nothing
                                                 --------  -------
     contained in this clause shall require Buyer to return Proprietary
     Information of Seller that is contained in any Products sold to Buyer.

               (C)  Buyer and Seller shall cooperate with each other in
     completing all outstanding obligations to customers of Buyer, including the
     fulfillment of each warranty term and condition.

18.  MISCELLANEOUS

     (a)  Amendment and Waiver. Any provision of this Agreement may be amended
          --------------------
and the observance of any provision of this Agreement may be waived (either
generally or any particular instance and either retroactively or prospectively)
only with the written consent of the parties. However, it is the intention of
the parties that this Agreement be controlling over additional or different
terms of any purchase order, confirmation, invoice or similar document, even if
accepted in writing by both parties, and that waivers and amendments shall be
effective only if made by non-preprinted agreements understood by both parties
to be an amendment or waiver.

     (b)  Governing Law and Legal Actions. This Agreement shall be governed by
          -------------------------------
and construed under the laws of the State of California and the United States
without regard to conflicts of laws provisions thereof. All actions or
proceedings arising in connection with this Agreement shall be tried and
litigated exclusively in the state or federal courts located in the County of
San Diego, State of California. The aforementioned choice of venue is intended
by the parties to be mandatory and not permissive in nature, thereby precluding
the possibility of litigation between the parties with respect to or arising our
of this Agreement in any jurisdiction other than that specified in this
paragraph. Each party hereby waives any right it may have to assert the doctrine
of forum non conveniens or similar doctrine or to object to venue with respect
to any proceeding brought in accordance with this paragraph, and stipulates and
acknowledges that it has had sufficient minimum contacts with California such
that the State and Federal courts located in the County of San Diego, State of
California shall have in personam jurisdiction over each of them for the purpose
of litigating any such dispute, controversy or proceeding. Each party hereby
authorizes and accepts service of process sufficient for personal jurisdiction
in any action against it as contemplated by this section by registered or
certified mail, return receipt requested, postage prepaid, to its address in the
pre-amble hereof or such other address as is provided in accordance with the
notice provisions hereof. Nothing herein shall affect the right of any party to
serve process in any other manner permitted by law. In any action or proceeding
to enforce rights under this Agreement, the prevailing party shall be entitled
to recover reasonable costs and attorney's fees.

     (c)  Headings. Headings used in this Agreement are for convenience of
reference only and will not affect the meaning or interpretation thereof.

     (d)  Notices. Any notice by either party to the other shall be in writing
          -------
and deemed given upon the earlier of (a) delivery or (b) four (4) calendar days
after such notice is mailed by registered or certified United States mail,
return receipt requested, postage prepaid, and

                                      -19-
<PAGE>

addressed to the addressee at its address set forth in the preamble to this
Agreement, provided that either party may change its address for notice by
giving the other party prior written notice of the new address in conformity
with the foregoing and the date upon which such new address will become
effective.

     (e)  Entire Agreement. This Agreement constitutes the entire agreement and
          ----------------
understanding between the parties hereto with respect to the subject matter
hereof and supersedes all proposals, oral or written, all negotiations,
conversations or discussions between or among the parties relating to the
subject matter of this Agreement and all past dealing or industry custom.

     (f)  Severability. If a court of competent jurisdiction finds any provision
          ------------
of this Agreement invalid, illegal or unenforceable, then such provision shall
be null and void but each other provision hereof not so affected shall be
enforced to the full extent permitted by applicable law.

     (g)  Force Majeure. Neither Seller nor Buyer shall be liable for any delays
          -------------
or failure to hereunder resulting from circumstances or causes beyond the
reasonable control of such party, including but not limited to those caused by
acts of God, act or omission of the other party or any third party, failure to
provide any cooperation needed by one party to the other party, fire, strike,
riots, flood, governmental interference, or unavailability or shortage of
materials, labor, fuel or power through normal commercial channels.

     (h)  Insurance. During the Term, Buyer and Seller shall each maintain
          ----------
comprehensive general liability insurance, including product liability
insurance, and workmen's compensation insurance in such amounts as are customary
for companies similarly situated.

     (i)  Counterparts. This Agreement may be executed in any number of
          ------------
counterparts, each of which shall be an original, but all of which together
shall constitute one instrument. Facsimile signatures on this Agreement will
have the same legal effect as original signatures thereon.

     (j)  No Alter Ego Liability. Seller acknowledges that Buyer is currently
          ----------------------
thinly capitalized and agrees that it will not assert any claim or cause of
action against Buyer's directors or officers under an "alter ego" theory.

                                      -20-
<PAGE>

     IN WITNESS WHEREOF, each of the parties hereto has executed this Agreement
as of the Effective Date.

<TABLE>
<CAPTION>
SELLER                                        BUYER
<S>                                           <C>
CardioDynamics International Corporation,     Profiles in Health, Inc.,
a California corporation                      A California corporation

By: /s/  Michael K. Perry                     By: /s/  Evon A. Kelly
    -------------------------------------         --------------------------------------
Name:  Michael K. Perry                       Name:  Evon A. Kelly
       ----------------------------------            -----------------------------------
Title: Chief Executive Officer                Title: President & Chief Executive Officer
       ----------------------------------            -----------------------------------
Date:  3/1/00                                  Date: 3/1/00
       ----------------------------------            -----------------------------------
</TABLE>

                                     -21-
<PAGE>

                                                CONFIDENTIAL TREATMENT REQUESTED

                                   EXHIBIT A

                                    PRICES
     Monitors

--------------------------------------------------------------------------------
              Quantity                          Price Per Monitor

--------------------------------------------------------------------------------
[CONFIDENTIAL TREATMENT REQUESTED]      [CONFIDENTIAL TREATMENT REQUESTED]
[CONFIDENTIAL TREATMENT REQUESTED]      [CONFIDENTIAL TREATMENT REQUESTED]
[CONFIDENTIAL TREATMENT REQUESTED]      [CONFIDENTIAL TREATMENT REQUESTED]
[CONFIDENTIAL TREATMENT REQUESTED]      [CONFIDENTIAL TREATMENT REQUESTED]
--------------------------------------------------------------------------------

     Electrodes

--------------------------------------------------------------------------------
              Quantity                          Price Per Electrodes

--------------------------------------------------------------------------------
[CONFIDENTIAL TREATMENT REQUESTED]      [CONFIDENTIAL TREATMENT REQUESTED]
[CONFIDENTIAL TREATMENT REQUESTED]      [CONFIDENTIAL TREATMENT REQUESTED]
[CONFIDENTIAL TREATMENT REQUESTED]      [CONFIDENTIAL TREATMENT REQUESTED]
[CONFIDENTIAL TREATMENT REQUESTED]      [CONFIDENTIAL TREATMENT REQUESTED]
--------------------------------------------------------------------------------

     The following amounts are the Deferred Amounts (as described in Section
4(e)(i)) with respect to the purchase price payable for Monitors and Electrodes
during the first 2 years of this Agreement:

<TABLE>
<CAPTION>
-------------------------------------------------------------------------------------------
         Year                   Monitors                          Electrode

-------------------------------------------------------------------------------------------
<S>               <C>                                 <C>
          1       [CONFIDENTIAL TREATMENT REQUESTED]  [CONFIDENTIAL TREATMENT REQUESTED]
          2       [CONFIDENTIAL TREATMENT REQUESTED]  [CONFIDENTIAL TREATMENT REQUESTED]
-------------------------------------------------------------------------------------------
</TABLE>

                                      -A-
<PAGE>

                                   EXHIBIT B

          CONVERTIBLE SECURED PROMISSORY NOTE AND SECURITY AGREEMENT

                           PROFILES IN HEALTH, INC.

     FOR VALUE RECEIVED, the undersigned, Profiles in Health, Inc., a California
corporation ("Maker"), hereby unconditionally promises to pay to the order of
CardioDynamics International Corporation, a California corporation, or any
subsequent holder hereof ("Holder"), in lawful money of the United States of
America, the principal amount of ______________ ($_________) initially, plus
such additional principal amount arising from time to time with respect to the
purchase by Maker of certain hemodynamic monitors and electrodes as provided for
in that certain Purchase Agreement made as of March 1, 2000 between Maker and
Holder (the "Purchase Agreement"), plus interest, as specified below.  Each
holder hereof is irrevocably authorized to record on Schedule A attached hereto,
or on a continuation thereof, the initial principal amount, each additional
principal amount arising from time to time as provided for in the Purchase
Agreement and each payment or prepayment (by cash or offset) of principal and
interest, provided that the failure of Holder to make, or an error in making,
any such recordation shall not affect the obligations of Maker hereunder.  All
such recordations shall, in the absence of manifest error, constitute conclusive
evidence of the accuracy of the information so recorded.  This Promissory Note
(this "Note") is the Note described in the Purchase Agreement, and evidences
indebtedness of the Maker for the deferred portion of the purchase price of the
hemodynamic monitors and electrodes as described in the Purchase Agreement.

          1. Interest.

               a.   The interest rate on this Note shall be the lesser of nine
percent (9%) and the maximum rate permitted by applicable law.  Payments of
interest only will be payable quarterly, commencing with interest accrued
through the quarter ending May 31, 2000, until the principal amount has been
paid in full.

               b.   Interest will accrue daily and will be calculated on the
unpaid principal amount on the basis of a 365 day year and the actual number of
days elapsed.

               c.   If any payment of principal or accrued interest under this
Note is not paid when due, then interest will thereafter accrue on the unpaid
portion of such payment of principal or interest at a rate equal to the rate
provided in Section 1(a), provided that the unpaid interest, so compounded, may
not result in total interest payable in excess of the maximum rate permitted by
law.  Such payment of principal and/or all accrued interest thereon will be
payable on Holder's demand.

          2. Payment.  All amounts due under this Note are payable as follows:

               a.   The principal amount and all interest accrued thereon shall
be due and payable on the earliest to occur of (a) ___________, 200__ [36 months
from date of first PO]; or (b) the date declared due and payable by Holder upon
the occurrence of an Event of Default (the "Due Date").
<PAGE>

               b.   The principal amount and any interest accrued thereon may be
prepaid by Maker in full or in part at any time and from time to time (the
"Prepayments") without premium or penalty upon at least thirty (30) days notice
to Holder, provided that all Prepayments made hereunder are first to be applied
to any accrued and unpaid interest outstanding on the date of such payment, and;
provided, further, that Holder shall have the option to convert all or any
portion of any Prepayment in accordance with the provisions set forth in Section
7 by providing Maker with notice of Holder's election to so convert prior to the
end of the 30-day notice period (the Prepayment Date).

               c.   Maker shall make all payments to Holder in immediately
available funds at CardioDynamics International Corporation, 6175 Nancy Ridge
Drive, Suite 300, San Diego, California, or at such other place as Holder may
designate from time to time in writing.  If any payment under this Note becomes
due on a Saturday or Sunday or a banking holiday in the State of California, the
maturity thereof will be extended to the next succeeding business day.

               d.   Maker agrees that if payment as required hereunder is not
paid within twenty (20) days after the due date thereof, Maker will pay a late
charge equal to One and one-half percent (1.5%) of the amount of the delinquent
payment.

          3. Events of Default.  If any of the following events shall occur
(herein individually referred to as an "Event of Default"), Holder may, so long
as such conditions exist, declare the entire principal amount and unpaid accrued
interest thereon immediately due and payable, by notice in writing to Maker:

               a.   Failure by Maker to make any payment hereunder when due and
payable if such default is not cured by Maker within twenty (20) days after
Holder has given Maker written notice of such default; or

               b.   Maker's insolvency; or

               c.   The institution by Maker of proceedings to be adjudicated as
bankrupt or insolvent, or the consent by Maker to the institution of bankruptcy
or insolvency proceedings against Maker or the filing by Maker of a petition or
answer or consent seeking reorganization or release under the federal Bankruptcy
Act, or any other similar federal or state law, or the consent by Maker to the
filing of any such petition or the appointment of a receiver, liquidator,
assignee, trustee or other similar official of Maker, or of any substantial part
of Maker's property, or the making by Maker of an assignment for the benefit of
creditors, or the taking of action by Maker in furtherance of any such action;
or

               d.   If, within sixty (60) days after the commencement of an
action against Maker (and service of process in connection therewith on Maker)
seeking any bankruptcy, insolvency, reorganization, liquidation, dissolution or
similar relief under any present or future statute, law or regulation, such
action shall not have been resolved in favor of Maker or all orders or
proceedings thereunder affecting the operations or the business of Maker stayed,
or if the stay of any such order or proceeding shall thereafter be set aside, or
if, within sixty (60) days after the appointment without the consent or
acquiescence of Maker of any

                                      -2-
<PAGE>

trustee, receiver or liquidator of Maker or of all or any substantial part of
the properties of Maker, such appointment shall not have been vacated; or

               e.   Any sale, transfer, lease, license or other disposition of
all or substantially all of the assets of Maker, other than to an entity in
which the current shareholders of Maker own at least 50% of the ownership
interests of such entity; or

               f.   Any transaction or series of related transactions as a
result of which any person who is not as of February __, 2000 a holder of at
least five percent (5%) of the capital stock of Maker acquires more than fifty
percent (50%) of the capital stock of Maker; or

               g.   Any direct or indirect merger, combination or other
reorganization of Maker with or into any other entity in which the holders of
the issued and outstanding shares of capital stock of Maker immediately prior to
any such transaction do not hold in excess of fifty percent (50%) of the issued
and outstanding shares of capital stock of the surviving or acquiring entity (on
an as-converted to common stock basis) following such transaction; or

               h.   The closing of the sale of the Common Stock of Maker ("the
"Common Stock") in a public offering registered under the Securities Act of
1933, as amended ("IPO"), subject to the limits on the amount deemed in default
set forth below; or

               i.   Maker's default under the Purchase Agreement, after
expiration of any cure periods as provided therein; or

               j.   Maker's failure to establish and maintain the separate
Deposit Accounts (as defined below) as required in Section 6(e); or

               k.   Maker's failure to provide Holder with the notice required
in Section 6(e) with respect to the establishment of Deposit Accounts; or

               l.   Maker's failure, other than as provided in Section 3(a), to
comply with any provision of this Note if such failure shall continue for a
period of twenty (20) business days following Holder's notice to Maker with
respect thereto.

     At such time as this Note becomes in default, the then unpaid principal and
interest shall, at the option of Holder, be immediately due and payable, all
without demand, presentment or notice, each of which is hereby waived by Maker,
and Holder shall have all other rights accorded under this Note and any other
agreement or by law, all of which rights shall be cumulative, except that in the
event of an IPO the amount in default shall be determined as follows:

     Amount of Net Proceeds to Maker            Default Amount Due to Holder
     -------------------------------            ----------------------------

        Less than $25,000,000                              $0

      $25,000,001 to $30,000,000                    25% of Note Amount

      $30,000,000 to $40,000,000                    50% of Note Amount

                                      -3-
<PAGE>

      $40,000,000 to $50,000,000                    75% of Note Amount

         $50,000,000 or more                       100% of Note Amount

The failure of Holder to exercise such option upon the occurrence of one or more
of such events shall not prevent its exercise upon the recurrence of such event
or events, or upon the occurrence of any other event specified above.  All sums
remaining unpaid on an accelerated Due Date shall bear interest at the rate
specified above.

          4.   Security for Obligations.  In order to secure the prompt payment
or performance in full when due (including the payment of amounts that would
become due but for the operation of the automatic stay under Section 362(a) of
the Bankruptcy Code, 11 U.S.C. (S) 362(a)) of all obligations of every nature of
Maker now or hereafter existing to Holder or its assignees, transferees and
successors under this Note, and all amendments, extensions or renewals hereof,
whether for principal, interest (including, without limitation, interest that,
but for the filing of a petition in bankruptcy with respect to Maker, would
accrue on such obligations), fees, expenses or otherwise, whether now existing
or hereafter arising, voluntary or involuntary, whether or not jointly owed with
others, direct or indirect, absolute or contingent, liquidated or unliquidated,
and whether or not from time to time decreased or extinguished and later
increased, created or incurred and all or any portion of such obligations that
are paid, to the extent all or any part of such payment is avoided or recovered
directly or indirectly from Holder as a preference, fraudulent transfer or
otherwise (all such obligations being the "Secured Obligations"), Maker hereby
grants to Holder a security interest in and to all right, title and interest of
Maker in the following property, whether now owned or existing or hereafter
acquired or arising and regardless of where located (all being collectively
referred to as the "Collateral"):

               a.   All "accounts" (as defined in the Uniform Commercial Code of
the State of California ("UCC")) now owned or hereafter created, acquired by
Maker arising directly from the utilization of the Products (as defined in the
Purchase Agreement) by Maker's customers including, without limitation, all of
the following now owned or hereafter created or acquired by Maker and arising
directly from such accounts:  (i) accounts receivable, contract rights, book
debts, notes, drafts, chattel paper and other obligations or indebtedness owing
to Maker; (ii) Maker's rights in, to and under all purchase orders for goods,
services or other property; (iii) Maker's rights to any goods, services or other
property represented by any of the foregoing (including returned or repossessed
goods and unpaid sellers' rights of rescission, replevin, reclamation and rights
of stoppage in transit); (iv) monies due to or to become due to Maker under all
contracts for the sale, lease, license, exchange or other disposition of goods
or other property and/or the performance of services (whether or not yet earned
by performance on the part of Maker); (v) uncertificated securities; and (vi)
proceeds of any of the foregoing and all collateral security and guaranties of
any kind given by any person with respect to any of the foregoing (the
"Accounts");

               b.   All contracts, undertakings or agreements in or under which
Maker may now or hereafter have any right, title or interest relating to the
terms of payment or the terms of performance of any Account (the "Contracts");

                                      -4-
<PAGE>

               c.   All "instruments", "chattel paper" or "letters of credit"
(each as defined in UCC) including, but not limited to, promissory notes,
drafts, bills of exchange and trade acceptances, now owned or hereafter acquired
by Maker with respect to the Accounts (the "Instruments");

               d.   All demand, time, savings, passbook or like accounts
maintained with a bank, savings and loan association, credit union or like
organization, other than an account evidenced by a negotiable certificate of
deposit, maintained solely with respect to the Accounts ("Deposit Accounts");
and

               e.   All proceeds of, and all other profits, rentals or receipts,
in whatever form, arising from the collection, sale, lease, exchange,
assignment, licensing or other disposition of, or realization upon, any of the
property described in subparts (a) through (d) above including, without
limitation, all claims of Maker against third parties for loss of, damage to or
destruction of, or for proceeds payable under, or unearned premiums with respect
to, policies of insurance with respect to any Collateral, in each case whether
now existing or hereafter arising (the "Proceeds").

          5. Security Interest.  This Note shall create a continuing security
interest in the Collateral and shall remain in full force and effect until the
final payment in full of the Secured Obligations. Upon the occurrence of any
Event of Default, Holder may exercise in respect of the Collateral all the
rights and remedies of a secured party on default under the UCC. Holder may, but
is not required to, pursue recourse or remedies against the Collateral as
provided herein and/or under applicable law, and Holder's pursuit or exhaustion
of recourse or remedies against the Collateral shall not be a condition to or
otherwise affect any obligation or liability of Maker. Upon the final payment in
full of the Secured Obligations, the security interest granted hereby shall
terminate and all security interests in the Collateral shall terminate.

          6. Holder's Rights; Limitations on Holder's Obligations.

               a.   Except as otherwise provided in this Note, Maker shall
continue to collect, at its own expense, all amounts due or to become due Maker
under the Accounts.  In connection with such collections, Maker may take (and,
after the occurrence of an Event of Default, at Holder's direction, shall take)
such action as Maker may deem necessary or advisable to enforce collection of
the Accounts.  After the occurrence of an Event of Default (i) all amounts and
proceeds (including Instruments) received by Maker with respect to the Accounts
shall be received in trust for the benefit of Holder, shall be segregated from
other funds of Maker and shall be forthwith paid over to Holder in the same form
as so received (with any necessary endorsement) and (ii) Maker shall not adjust,
settle or compromise the amount or payment of any Account, or release wholly or
partially any customer or obligor thereof, or allow any credit or discount
thereon without the prior consent of Holder, which consent shall not be
unreasonably withheld.

               b.   It is expressly agreed by Maker that, notwithstanding
anything herein to the contrary, Maker shall remain liable under each Contract
to observe and perform all the conditions and obligations to be observed and
performed by it thereunder, and Holder shall have no obligation or liability
under any Contract or by reason of or arising out of this Note or

                                      -5-
<PAGE>

the granting herein of a security interest therein or the receipt by Holder of
any payment relating to any Contract pursuant hereto, and Holder shall not be
required or obligated in any manner to take any action to collect or enforce any
performance or the payment of any amounts which may have been assigned to it or
to which it may be entitled at any time or times.

               c.   Upon the occurrence and during the continuation of an Event
of Default, Holder may notify (and Maker shall, if requested by Holder, notify)
Account makers of Maker, parties to the Contracts of Maker and obligors in
respect of Instruments of Maker, that the Accounts and the right, title and
interest of Maker in and under the Contracts, Instruments and Proceeds have been
assigned to Holder and that payments shall be made directly to Holder.

               d.   Maker hereby irrevocably appoints Holder as Maker's
attorney-in-fact, with full authority in the place and stead of Maker and in the
name of Maker, Holder or otherwise, from time to time in Holder's discretion to
take any action and to execute any instrument that Holder may deem reasonably
necessary or advisable to accomplish the purposes of the security interest
granted in this Note and to protect, preserve or realize upon the Collateral.
This power, being coupled with an interest, is irrevocable so long as this Note
shall remain outstanding.

               e.   Make shall maintain separate Deposit Accounts for all monies
received in respect of Accounts and Contracts.  Attached hereto as Schedule B is
the form of Notice of Security Interest in Deposit Account to be used by Holder
in giving notice of its security interest in Deposit Accounts.  Maker shall
provide to Holder the name and address of all depository institutions holding
Maker's deposit accounts prior to delivery of this Note and shall provide to
Holder the name and address of all depository institutions with whom Maker
intends to open a Deposit Account at least ten (10) days prior to opening such
account.

          7.   Conversion.   At the option of Holder, (i) at any time prior to
the Prepayment Date with respect to a Prepayment all or a portion of the
Prepayment amount and (ii) on or after the Due Date all or a portion of the
unpaid principal balance and/or accrued but unpaid interest under this Note may
be converted into fully paid and nonassessable shares of the Common Stock, at a
conversion price equal to the common equivalent per share purchase price paid by
the purchasers in Maker's next financing transaction (currently estimated to be
$1.50 per share), subject to adjustment as provided in Section 6(c) below;
                                                       ------------
provided, however, that in no event shall Holder be entitled to convert
principal and interest which, in the aggregate, represents more than three
percent (3%) of the issued and outstanding capital stock of Maker as of the
Effective Date of the Purchase Agreement (the "Conversion"). Any principal and
interest not converted shall be paid to Holder in cash on the Due Date or the
Prepayment Date, as the case may be.

               a.   The Conversion will be subject to the requirement that, if
at any time Maker determines, in its reasonable discretion, that the listing,
registration or qualification of the Common Stock upon any securities exchange
or interdealer quotation system or under any federal, state or foreign law, or
the consent or approval of any government or regulatory body, is necessary as a
condition of, or in connection with, the issuance of the Common Stock, the
Conversion may not be effected unless and until such listing, registration,
qualification, consent or approval has been effected or obtained free of any
conditions not reasonably acceptable to

                                      -6-
<PAGE>

Maker. Maker will use its reasonable efforts to seek to obtain from the
appropriate governmental and regulatory agencies any requisite qualifications,
consents, approvals or authorizations in order to issue and sell such number of
shares of its Common Stock as is sufficient to satisfy the requirements of this
Section 7. The inability of Maker to obtain any such qualifications, consents,
approvals or authorizations, after exercising its reasonable efforts, will
relieve the Company of any liability in respect of the nonissuance or sale of
the Common Stock.

               b.   Maker will be under no obligation to register or qualify the
issuance of the Common Stock contemplated hereunder under the Securities Act or
applicable state securities laws.  Unless the issuance of the Common Stock has
been registered under the Securities Act and qualified or registered under
applicable state securities laws, Maker shall be under no obligation to effect
the Conversion unless the Common Stock may be issued pursuant to an applicable
exemption from such registration or qualification requirements.  In connection
with any such exempt issuance, Maker may require Holder to provide a written
representation and undertaking to Maker, satisfactory in form and scope to
Maker, that Holder is acquiring such Common Stock for Holder's own account as an
investment and not with a view to, or for sale in connection with, the
distribution of any such securities, and that Holder will make no transfer of
the same except in compliance with any rules and regulations in force at the
time of such transfer under the Securities Act and other applicable law, and
that if the Common Stock is issued without registration, a legend to this effect
may be endorsed upon the securities so issued, and to the effect of any
additional representations that are appropriate in light of applicable
securities laws and rules.  Maker may also order its transfer agent to stop
transfers of such shares.  Maker may also require Holder to provide it such
information and other documents as Maker may request in order to satisfy Maker
as to the investment sophistication and experience of Holder and as to any other
conditions for compliance with any such exemptions from registration or
qualification.

               c.   The conversion price and the number of shares into which
this Note may be converted are subject to adjustment from time to time as
follows:

          (i)   If Maker, at any time while this Note, or any portion thereof,
     remains outstanding and unexpired by reclassification of securities or
     otherwise, shall change any of the securities as to which conversion rights
     under this Note exist into the same or a different number of securities or
     any other class or classes, this Note shall thereafter represent the right
     to acquire such number and kinds of securities that were subject to the
     conversion rights under this Note immediately prior to such
     reclassification or other change and the conversion price therefor shall be
     appropriately adjusted.

          (ii)  If Maker, at any time while this Note, or any portion thereof,
     remains outstanding and unexpired shall split, subdivide or combine the
     securities as to which conversion rights under this Note exist into a
     different number of securities of the same class, then (A) in the case of a
     split or subdivision, the conversion price for such securities shall be
     proportionately decreased and the securities issuable upon conversion of
     this Note shall be proportionately increased, and (B) in the case of a
     combination, the conversion price for such securities shall be
     proportionately increased and the securities issuable upon conversion of
     this Note shall be proportionately decreased.

                                      -7-
<PAGE>

          8.   Remedies.  No delay or omission on the part of Holder in
exercising any right or remedy under this Note or under any other agreement
securing this Note or applicable law will operate as a waiver of such right or
remedy or of any other right or remedy. No single or partial exercise of any
power under this Note or any other agreement securing this Note or applicable
law will preclude other or further exercise thereof or the exercise of any other
power. Holder will at all times have the right to proceed against any portion of
the security held herefor in such order and in such manner as Holder may
determine in Holder's sole discretion, without waiving any rights with respect
to any other security. The release of any party liable under this Note will not
operate to release any other party liable under this Note.

          9.   Modification and Termination.  This Note may not be modified or
terminated except by an agreement in writing signed by Maker and Holder, except
that Maker and any sureties or guarantors of this Note consent to all extensions
without notice for any period or periods of time and to the acceptance of
partial payments before or after maturity, and to the acceptance, release, and
substitution of security, all without prejudice to Holder. Holder will have the
right to deal in any way, at any time, with Maker, or with any surety or
guarantor hereof, without notice to any other party, and to grant any such party
any extensions of time for payment of any of the indebtedness hereunder, or to
grant any other indulgences or forbearances whatsoever, without notice to any
other party and without in any way affecting the liability of any such party.

          10.  Assignment.  Maker may not assign its obligations hereunder
without the written consent of Holder. For purposes hereof, the transfer of all
or substantially all of the assets of Maker or a merger or consolidation or
reorganization of Maker or a transfer to a parent or subsidiary of Maker shall
constitute an assignment to the transferee of such assets or the surviving
entity of such merger or consolidation or reorganization or such parent or
subsidiary requiring consent of Holder hereunder.

          11.  Usury.  All agreements between Maker and the holder hereof are
expressly limited so that in no contingency or event whatsoever, whether by
reason of advancement of the proceeds hereof, acceleration of maturity of the
unpaid principal balance hereof, or otherwise, will the amount paid or agreed to
be paid to the holder hereof for the use, forbearance or detention of money
exceed the highest lawful rate permissible under applicable usury laws. If, from
any circumstances whatsoever, fulfillment of any provision of this Note or any
security agreement or guaranty securing this Note, at the time performance of
such provision is due, involves transcending the limit of validity prescribed by
law which a court of competent jurisdiction may deem applicable hereto, then,
the obligation to be fulfilled will be reduced to the limit of such validity.
Furthermore, if, from any circumstances whatsoever, Holder ever receives as
interest an amount which would exceed the highest lawful rate, the amount which
would be excessive interest will be applied to the reduction of the unpaid
principal balance due hereunder and not to the payment of interest. This
provision controls every other provision of all agreements between Maker and
Holder.

          12.  Waiver.  Diligence, presentment, protest, demand, dishonor,
nonpayment, and notice of every kind are waived by all makers, sureties,
guarantors, and endorsers of this Note to the fullest extent permitted by
applicable law. To the fullest extent permitted by law, the defense of the
statute of limitations is waived by Maker.

                                      -8-
<PAGE>

          13.  Successors and Assigns.  This Note will be binding upon the
successors and assigns of Maker and inure to the benefit of Holder, and its
successors, endorsees, and assigns.

          14.  Severability.  If any term or provision of this Note is held
invalid, illegal, or unenforceable, the validity of all other terms and
provisions hereof will in no way be affected thereby.

          15.  Other Obligations.  Performance under this Note is not intended
and is not to be construed as an accord and satisfaction or other release or
discharge of any obligations or indebtedness of Maker to Holder not otherwise
evidenced specifically.

          16.  Governing Law.  This Note is to be governed by, construed under,
and enforced in accordance with, the laws of the State of California without
regard to its conflicts-of-laws principles. Any legal action or proceeding
arising out of or in connection with this Note must be brought exclusively in
the courts of the State of California or the Federal courts of the United States
of America sitting in San Diego County, California. Maker hereby irrevocably
submits to the jurisdiction of each such court, and agrees that any summons,
pleading, judgment, memorandum of law, or other paper relevant to any such
action or proceeding, including without limitation, service of process
sufficient for personal jurisdiction in any action against Maker, will be
sufficiently served if delivered to the Maker by certified or registered mail
(with return receipt) at its principal executive offices. Nothing in the
preceding sentence will affect the right of any party to proceed in any
jurisdiction for the enforcement or execution of any judgment, decree or order
made by a court specified in said sentence.

          17.  Costs of Collection.  Maker promises to pay the costs (including
without limitation reasonable attorneys' fees and costs) of enforcement and
collection of this Note and the protection or realization of any collateral or
other security in case of any breach or default by Maker hereunder.

          18.  Reversal of Payments.  If Holder receives any payments or rents,
issues, profits or proceeds of Collateral which are subsequently invalidated,
declared to be fraudulent or preferential, set aside or required to be paid to a
trustee, receiver or any other party under any bankruptcy law, common law,
equitable cause or otherwise, then, to such extent, the obligations or part
thereof intended to be satisfied by such payments or proceeds shall be reserved
and continue as if such payments or proceeds had not been received by Holder.

          19.  Section Headings and Captions.  The section headings and captions
contained in this Note are solely for convenience of reference and are not to
affect the meaning or interpretation of this Note or of any term or provision
hereof.

          20.  Waiver of Jury Trial/Waiver of Objection to Venue.  MAKER WAIVES
THE RIGHT TO A TRIAL BY JURY OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR
ARISING OUT OF OR IN CONNECTION WITH THIS NOTE, AND ANY RIGHT MAKER MAY HAVE TO
ASSERT THE DOCTRINE OF FORUM NON-CONVENIENS OR TO OBJECT TO VENUE TO THE EXTENT
ANY PROCEEDING IS BROUGHT HEREUNDER.

                                      -9-
<PAGE>

                                        MAKER
                                        Profiles in Health, Inc.
                                        a California corporation

                                        By: _______________________________
                                        Name: _____________________________
                                        Title: ____________________________

                                     -10-
<PAGE>

                                  SCHEDULE A

--------------------------------------------------------------------------------
                                 Amount of        Amount of
                                  Interest      Principal Paid,
                  Amount of      Charged on       Prepaid or
                  Advance of     Outstanding     Reduced by        Outstanding
     Date          Principal       Balance         Offset            Balance

--------------------------------------------------------------------------------

                                     -11-

<PAGE>

                                  SCHEDULE B

            Form of Notice of Security Interest In Deposit Account

                                    [Date]

Via Telecopier and Certified Mail - Return Receipt Requested
------------------------------------------------------------

[Insert name and address of applicable depository institution]

Attn:      [Name to be inserted]

      Re:  Profiles in Health, Inc.
           [Insert and account number]

To Whom It May Concern:

     Notice is hereby given that CardioDynamics International Corporation has a
security interest in deposit accounts of Profiles in Health, Inc., including any
such deposit accounts which may be maintained at [insert name of depository
institution].  File-stamped copies of UCC-1 Financing Statements for
CardioDynamics International, Inc. are enclosed for your records.  Please
contact the undersigned with any questions you may have.

                              Very truly yours,

                              ______________________

Enclosures

                                     -12-Exhibit 4.1

THIS WARRANT AND THE SHARES  ISSUABLE UPON THE EXERCISE OF THIS WARRANT HAVE NOT
BEEN  REGISTERED  UNDER  THE  SECURITIES  ACT OF 1933,  AS  AMENDED.  EXCEPT  AS
OTHERWISE SET FORTH  HEREIN,  NEITHER THIS WARRANT NOR ANY OF SUCH SHARES MAY BE
SOLD,  TRANSFERRED  OR  ASSIGNED  IN THE  ABSENCE OF AN  EFFECTIVE  REGISTRATION
STATEMENT FOR SUCH SECURITIES UNDER SAID ACT OR, AN OPINION OF COUNSEL, IN FORM,
SUBSTANCE   AND  SCOPE,   CUSTOMARY   FOR  OPINIONS  OF  COUNSEL  IN  COMPARABLE
TRANSACTIONS,  THAT  REGISTRATION  IS NOT REQUIRED UNDER SUCH ACT OR UNLESS SOLD
PURSUANT TO RULE 144 UNDER SUCH ACT.

                                                                        Right to
                                                                        Purchase
                                                                      __________
                                                                       Shares of
                                                                   Common Stock,
                                                                 par value $.001
                                                                       per share

                             STOCK PURCHASE WARRANT

     THIS CERTIFIES THAT, for value received,  ______________________________ or
his  registered  assigns,  is entitled to purchase from SKYMALL,  INC., a Nevada
corporation (the "Company"),  at any time or from time to time during the period
specified in Paragraph 2 hereof,  ______________________________________ (_____)
fully paid and  nonassessable  shares of the Company's  Common Stock,  par value
$.001 per share (the "Common  Stock"),  at an exercise  price of $7.50 per share
(the "Exercise Price"). The term "Warrant Shares," as used herein, refers to the
shares of  Common  Stock  purchasable  hereunder.  The  Warrant  Shares  and the
Exercise Price are subject to adjustment as provided in Paragraph 4 hereof.  The
term Warrants means this Stock Purchase Warrant.

     This Warrant is subject to the following terms, provisions, and conditions:

     1.   MANNER OF  EXERCISE;  ISSUANCE  OF  CERTIFICATES;  PAYMENT FOR SHARES.
Subject to the  provisions  hereof,  this Warrant may be exercised by the holder
hereof,  in whole or in part, by the surrender of this Warrant,  together with a
completed  exercise  agreement  in  the  form  attached  hereto  (the  "Exercise
Agreement"),  to the Company during normal business hours on any business day at
the Company's principal executive offices (or such other office or agency of the
Company  as it may  designate  by notice  to the  holder  hereof),  and upon (i)
payment to the Company in cash,  by certified or official  bank check or by wire
transfer  for the account of the Company of the  Exercise  Price for the Warrant
Shares specified in the Exercise  Agreement or (ii) delivery to the Company of a
written  notice of an election to effect a  "Cashless  Exercise"  (as defined in
Section 11(c) below) for the Warrant Shares specified in the Exercise Agreement.
The  Warrant  Shares so  purchased  shall be  deemed to be issued to the  holder
hereof or such holder's designee,  as the record owner of such shares, as of the
close of business on the date on which this Warrant shall have been surrendered,
the completed  Exercise Agreement  shall have been  delivered, and payment shall

<PAGE>

have been made for such shares (or an election to effect a Cashless Exercise has
been made) as set forth above. Certificates for the Warrant Shares so purchased,
representing the aggregate number of shares specified in the Exercise Agreement,
shall be delivered to the holder hereof within a reasonable  time, not exceeding
two (2) business  days,  after this Warrant  shall have been so  exercised.  The
certificates so delivered shall be in such  denominations as may be requested by
the holder  hereof and shall be  registered  in the name of such  holder or such
other name as shall be  designated  by such holder.  If this Warrant  shall have
been exercised only in part, then, unless this Warrant has expired,  the Company
shall, at its expense, at the time of delivery of such certificates,  deliver to
the holder a new Warrant representing the number of shares with respect to which
this Warrant shall not then have been exercised.

          Notwithstanding  anything in this Warrant to the contrary, in no event
shall the Holder of this  Warrant be  entitled  to exercise a number of Warrants
(or portions  thereof) in excess of the number of Warrants (or portions thereof)
upon  exercise  of which the sum of (i) the  number  of  shares of Common  Stock
beneficially  owned by the  Holder  and its  affiliates  and (ii) the  number of
shares of Common  Stock  issuable  upon  exercise of the  Warrants  (or portions
thereof) with respect to which the determination described herein is being made,
would result in  beneficial  ownership by the Holder and its  affiliates of more
than 4.9% of the  outstanding  shares  of  Common  Stock.  For  purposes  of the
immediately  preceding  sentence,  beneficial  ownership  shall be determined in
accordance  with  Section  13(d) of the  Securities  Exchange  Act of  1934,  as
amended, and Regulation 13D-G thereunder, except as otherwise provided in clause
(i) hereof.

     2.   PERIOD OF EXERCISE.  This Warrant is  exercisable  at any time or from
time to time on or after the date on which this Warrant is issued and  delivered
(the "Issue  Date") and before 5:00 p.m.,  New York City time on the third (3rd)
anniversary of the Issue Date (the "Exercise Period").

     3.   CERTAIN  AGREEMENTS OF THE COMPANY.  The Company hereby  covenants and
agrees as follows:

          (a) SHARES TO BE FULLY PAID. All Warrant Shares will, upon issuance in
accordance with the terms of this Warrant,  be validly  issued,  fully paid, and
nonassessable  and free from all taxes,  liens,  and charges with respect to the
issue thereof.

          (b)  RESERVATION OF SHARES.  During the Exercise  Period,  the Company
shall at all times have  authorized,  and  reserved  for the purpose of issuance
upon exercise of this Warrant,  a sufficient number of shares of Common Stock to
provide for the exercise of this Warrant.

          (c)  LISTING.  The Company  shall  promptly  secure the listing of the
shares of Common Stock  issuable upon exercise of the Warrant upon each national
securities  exchange or automated quotation system, if any, upon which shares of
Common  Stock are then  listed  (subject to  official  notice of  issuance  upon
exercise of this  Warrant)  and shall  maintain,  so long as any other shares of

                                     Page 2
<PAGE>

Common Stock shall be so listed, such listing of all shares of Common Stock from
time to time issuable  upon the exercise of this Warrant;  and the Company shall
so list on each national  securities  exchange or automated quotation system, as
the case may be, and shall maintain such listing of, any other shares of capital
stock of the Company  issuable  upon the exercise of this Warrant if and so long
as any  shares of the same  class  shall be listed on such  national  securities
exchange or automated quotation system.

          (d)  CERTAIN ACTIONS PROHIBITED. The Company will not, by amendment of
its charter or through any  reorganization,  transfer of assets,  consolidation,
merger, dissolution, issue or sale of securities, or any other voluntary action,
avoid or seek to avoid the  observance or  performance of any of the terms to be
observed  or  performed  by it  hereunder,  but will at all times in good  faith
assist in the  carrying  out of all the  provisions  of this  Warrant and in the
taking of all such action as may  reasonably  be requested by the holder of this
Warrant in order to protect the exercise privilege of the holder of this Warrant
against dilution or other  impairment,  consistent with the tenor and purpose of
this Warrant.  Without limiting the generality of the foregoing, the Company (i)
will not increase the par value of any shares of Common  Stock  receivable  upon
the exercise of this Warrant above the Exercise  Price then in effect,  and (ii)
will take all such actions as may be necessary or  appropriate in order that the
Company may validly and  legally  issue fully paid and  nonassessable  shares of
Common Stock upon the exercise of this Warrant.

          (e)  SUCCESSORS  AND  ASSIGNS.  This  Warrant will be binding upon any
entity succeeding to the Company by merger, consolidation, or acquisition of all
or substantially all the Company's assets.

     4.   ANTIDILUTION  PROVISIONS.  During the  Exercise  Period,  the Exercise
Price and the number of Warrant Shares shall be subject to adjustment  from time
to time as provided in this Paragraph 4.

          In the event that any  adjustment  of the  Exercise  Price as required
herein results in a fraction of a cent,  such Exercise Price shall be rounded up
to the nearest cent.

          (a)  ADJUSTMENT  OF EXERCISE  PRICE AND NUMBER OF SHARES UPON ISSUANCE
OF COMMON  STOCK.  Except as  otherwise  provided  in  Paragraphs  4(c) and 4(e)
hereof, if and whenever on or after the Issue Date of this Warrant,  the Company
issues or sells,  or in accordance  with Paragraph 4(b) hereof is deemed to have
issued  or sold,  any  shares  of Common  Stock  for no  consideration  or for a
consideration per share (before deduction of reasonable  expenses or commissions
or underwriting  discounts or allowances in connection  therewith) less than the
Market  Price  (as  hereinafter  defined)  on the date of  issuance  (or  deemed
issuance) of such Common Stock (a "Dilutive  Issuance"),  then  immediately upon
the Dilutive Issuance,  the Exercise Price will be reduced to a price determined
by multiplying  the Exercise Price in effect  immediately  prior to the Dilutive
Issuance by a fraction, (i) the numerator of which is an amount equal to the sum

                                     Page 3
<PAGE>

of (x) the number of shares of Common  Stock  actually  outstanding  immediately
prior  to the  Dilutive  Issuance,  plus  (y)  the  quotient  of  the  aggregate
consideration, calculated as set forth in Paragraph 4(b) hereof, received by the
Company  upon such  Dilutive  Issuance  divided  by the  Market  Price in effect
immediately prior to the Dilutive Issuance, and (ii) the denominator of which is
the total number of shares of Common Stock Deemed Outstanding (as defined below)
immediately after the Dilutive Issuance.

          (b)  EFFECT ON  EXERCISE  PRICE OF CERTAIN  EVENTS.  For  purposes  of
determining  the  adjusted  Exercise  Price under  Paragraph  4(a)  hereof,  the
following will be applicable:

               (i)  ISSUANCE OF RIGHTS OR OPTIONS.  If the Company in any manner
issues or grants any  warrants,  rights or options,  whether or not  immediately
exercisable,  to subscribe for or to purchase  Common Stock or other  securities
convertible  into or exchangeable  for Common Stock  ("Convertible  Securities")
(such  warrants,  rights and options to  purchase  Common  Stock or  Convertible
Securities are hereinafter referred to as "Options") and the price per share for
which  Common  Stock is issuable  upon the exercise of such Options is less than
the Market  Price on the date of  issuance  or grant of such  Options,  then the
maximum total number of shares of Common Stock issuable upon the exercise of all
such Options will,  as of the date of the issuance or grant of such Options,  be
deemed to be  outstanding  and to have been  issued and sold by the  Company for
such price per share.  For purposes of the  preceding  sentence,  the "price per
share for which Common Stock is issuable  upon the exercise of such  Options" is
determined by dividing (i) the total amount,  if any,  received or receivable by
the Company as  consideration  for the issuance or granting of all such Options,
plus the minimum aggregate amount of additional  consideration,  if any, payable
to the Company  upon the  exercise  of all such  Options,  plus,  in the case of
Convertible  Securities issuable upon the exercise of such Options,  the minimum
aggregate  amount of  additional  consideration  payable upon the  conversion or
exchange  thereof  at  the  time  such   Convertible   Securities  first  become
convertible  or  exchangeable,  by (ii) the  maximum  total  number of shares of
Common  Stock  issuable  upon the exercise of all such  Options  (assuming  full
conversion of Convertible Securities,  if applicable).  No further adjustment to
the  Exercise  Price will be made upon the actual  issuance of such Common Stock
upon  the  exercise  of such  Options  or upon the  conversion  or  exchange  of
Convertible Securities issuable upon exercise of such Options.

               (ii) ISSUANCE OF  CONVERTIBLE  SECURITIES.  If the Company in any
manner issues or sells any  Convertible  Securities,  whether or not immediately
convertible  (other  than  where  the same are  issuable  upon the  exercise  of
Options) and the price per share for which  Common  Stock is issuable  upon such
conversion  or exchange is less than the Market Price on the date of issuance of
such Convertible  Securities,  then the maximum total number of shares of Common
Stock  issuable  upon  the  conversion  or  exchange  of  all  such  Convertible
Securities will, as of the date of the issuance of such Convertible  Securities,
be deemed to be outstanding  and to have been issued and sold by the Company for

                                     Page 4
<PAGE>

such price per share. For the purposes of the preceding sentence, the "price per
share for which Common Stock is issuable  upon such  conversion  or exchange" is
determined by dividing (i) the total amount,  if any,  received or receivable by
the Company as  consideration  for the issuance or sale of all such  Convertible
Securities,  plus the minimum aggregate amount of additional  consideration,  if
any,  payable to the Company upon the conversion or exchange thereof at the time
such Convertible  Securities first become  convertible or exchangeable,  by (ii)
the maximum total number of shares of Common Stock  issuable upon the conversion
or exchange of all such  Convertible  Securities.  No further  adjustment to the
Exercise  Price will be made upon the actual  issuance of such Common Stock upon
conversion or exchange of such Convertible Securities.

               (iii) CHANGE IN OPTION PRICE OR  CONVERSION  RATE.  If there is a
change at any time in (i) the amount of additional  consideration payable to the
Company  upon the  exercise  of any  Options;  (ii)  the  amount  of  additional
consideration, if any, payable to the Company upon the conversion or exchange of
any  Convertible  Securities;  or  (iii)  the  rate  at  which  any  Convertible
Securities are  convertible  into or  exchangeable  for Common Stock (other than
under or by reason of  provisions  designed to protect  against  dilution),  the
Exercise  Price in effect at the time of such change will be  readjusted  to the
Exercise  Price which would have been in effect at such time had such Options or
Convertible  Securities still outstanding  provided for such changed  additional
consideration  or  changed  conversion  rate,  as the case  may be,  at the time
initially granted, issued or sold.

               (iv) TREATMENT  OF EXPIRED  OPTIONS AND  UNEXERCISED  CONVERTIBLE
SECURITIES. If, in any case, the total number of shares of Common Stock issuable
upon exercise of any Option or upon  conversion  or exchange of any  Convertible
Securities is not, in fact,  issued and the rights to exercise such Option or to
convert  or  exchange  such   Convertible   Securities  shall  have  expired  or
terminated, the Exercise Price then in effect will be readjusted to the Exercise
Price  which  would  have  been in  effect  at the  time of such  expiration  or
termination had such Option or Convertible Securities, to the extent outstanding
immediately  prior to such  expiration or termination  (other than in respect of
the actual  number of shares of Common Stock issued upon  exercise or conversion
thereof), never been issued.

               (v)  CALCULATION OF CONSIDERATION  RECEIVED. If any Common Stock,
Options or  Convertible  Securities  are issued,  granted or sold for cash,  the
consideration  received therefor for purposes of this Warrant will be the amount
received by the Company  therefor,  before deduction of reasonable  commissions,
underwriting  discounts  or  allowances  or other  reasonable  expenses  paid or
incurred by the Company in connection with such issuance, grant or sale. In case
any Common Stock,  Options or  Convertible  Securities  are issued or sold for a
consideration  part or all of which shall be other than cash,  the amount of the
consideration  other than cash received by the Company will be the fair value of

                                     Page 5
<PAGE>

such consideration,  except where such consideration consists of securities,  in
which case the  amount of  consideration  received  by the  Company  will be the
Market  Price  thereof  as of the date of  receipt.  In case any  Common  Stock,
Options or Convertible Securities are issued in connection with any acquisition,
merger or consolidation in which the Company is the surviving  corporation,  the
amount of  consideration  therefor  will be deemed to be the fair  value of such
portion of the net assets and business of the  non-surviving  corporation  as is
attributable  to such Common Stock,  Options or Convertible  Securities,  as the
case may be. The fair value of any  consideration  other than cash or securities
will be determined in good faith by the Board of Directors of the Company.

               (vi) EXCEPTIONS TO ADJUSTMENT OF EXERCISE PRICE. No adjustment to
the Exercise  Price will be made (i) upon the exercise of any warrants,  options
or  convertible  securities  granted,  issued  and  outstanding  on the  date of
issuance  of this  Warrant;  (ii)  upon the  grant or  exercise  of any stock or
options which may hereafter be granted or exercised  under any employee  benefit
plan of the Company now existing or to be implemented in the future,  so long as
the  issuance  of such  stock  or  options  is  approved  by a  majority  of the
independent  members of the Board of  Directors  of the Company or a majority of
the  members  of a  committee  of  independent  directors  established  for such
purpose;  or (iii) upon the exercise of the Warrants or the securities issued or
issuable pursuant to the Securities Purchase Agreement.

          (c)  SUBDIVISION OR COMBINATION OF COMMON STOCK. If the Company at any
time  subdivides  (by  any  stock  split,   stock  dividend,   recapitalization,
reorganization,  reclassification  or  otherwise)  the  shares of  Common  Stock
acquirable  hereunder into a greater number of shares,  then,  after the date of
record for effecting such subdivision,  the Exercise Price in effect immediately
prior to such subdivision will be proportionately reduced. If the Company at any
time  combines  (by  reverse  stock  split,  recapitalization,   reorganization,
reclassification  or otherwise) the shares of Common Stock acquirable  hereunder
into a smaller  number of shares,  then,  after the date of record for effecting
such  combination,  the  Exercise  Price  in  effect  immediately  prior to such
combination will be proportionately increased.

          (d)  ADJUSTMENT  IN NUMBER OF  SHARES.  Upon  each  adjustment  of the
Exercise  Price  pursuant to the  provisions of this  Paragraph 4, the number of
shares of Common Stock  issuable upon exercise of this Warrant shall be adjusted
by multiplying a number equal to the Exercise Price in effect  immediately prior
to such  adjustment  by the  number  of shares of  Common  Stock  issuable  upon
exercise of this Warrant  immediately  prior to such adjustment and dividing the
product so obtained by the adjusted Exercise Price.

          (e)  CONSOLIDATION,  MERGER OR SALE. In case of any  consolidation  of
the Company  with,  or merger of the Company into any other  corporation,  or in
case of any sale or conveyance of all or substantially  all of the assets of the
Company  other than in  connection  with a plan of complete  liquidation  of the
Company,  then  as  a  condition  of  such  consolidation,  merger  or  sale  or

                                     Page 6
<PAGE>

conveyance,  adequate  provision will be made whereby the holder of this Warrant
will have the right to acquire and receive upon exercise of this Warrant in lieu
of the  shares of  Common  Stock  immediately  theretofore  acquirable  upon the
exercise of this Warrant,  such shares of stock,  securities or assets as may be
issued or payable  with  respect to or in  exchange  for the number of shares of
Common Stock immediately  theretofore acquirable and receivable upon exercise of
this  Warrant had such  consolidation,  merger or sale or  conveyance  not taken
place. In any such case, the Company will make  appropriate  provision to insure
that the provisions of this Paragraph 4 hereof will  thereafter be applicable as
nearly as may be in  relation  to any shares of stock or  securities  thereafter
deliverable  upon the exercise of this Warrant.  The Company will not effect any
consolidation,  merger or sale or  conveyance  unless prior to the  consummation
thereof,  the successor or acquiring  entity (if other than the Company) and, if
an entity  different  from the successor or acquiring  entity,  the entity whose
capital  stock or assets  the  holders of the Common  Stock of the  Company  are
entitled  to  receive  as a  result  of such  consolidation,  merger  or sale or
conveyance  assumes by written instrument the obligations under this Paragraph 4
and the  obligations  to deliver to the holder of this  Warrant  such  shares of
stock, securities or assets as, in accordance with the foregoing provisions, the
holder may be entitled to acquire.

          (f)  DISTRIBUTION OF ASSETS. In case the Company shall declare or make
any distribution of its assets  (including cash) to holders of Common Stock as a
partial liquidating  dividend,  by way of return of capital or otherwise,  then,
after  the  date  of  record  for  determining  stockholders  entitled  to  such
distribution,  but prior to the date of distribution, the holder of this Warrant
shall be entitled  upon  exercise of this Warrant for the purchase of any or all
of the shares of Common  Stock  subject  hereto,  to receive  the amount of such
assets  which  would have been  payable to the holder had such  holder  been the
holder of such shares of Common  Stock on the record date for the  determination
of stockholders entitled to such distribution.

          (g)  NOTICE OF  ADJUSTMENT.  Upon the  occurrence  of any event  which
requires any adjustment of the Exercise Price,  then, and in each such case, the
Company shall give notice  thereof to the holder of this  Warrant,  which notice
shall state the Exercise Price  resulting from such  adjustment and the increase
or  decrease  in the number of  Warrant  Shares  purchasable  at such price upon
exercise,  setting forth in reasonable  detail the method of calculation and the
facts upon which such calculation is based.  Such calculation shall be certified
by the chief financial officer of the Company.

          (h)  MINIMUM  ADJUSTMENT  OF  EXERCISE  PRICE.  No  adjustment  of the
Exercise  Price shall be made in an amount of less than 1% of the Exercise Price
in effect at the time such adjustment is otherwise  required to be made, but any
such lesser  adjustment  shall be carried  forward and shall be made at the time
and  together  with the next  subsequent  adjustment  which,  together  with any
adjustments  so  carried  forward,  shall  amount  to not  less  than 1% of such
Exercise Price.

                                     Page 7
<PAGE>

          (i)  NO FRACTIONAL SHARES. No fractional shares of Common Stock are to
be issued upon the exercise of this  Warrant,  but the Company  shall pay a cash
adjustment in respect of any fractional  share which would otherwise be issuable
in an amount equal to the same fraction of the Market Price of a share of Common
Stock on the date of such exercise.

          (j)  OTHER NOTICES. In case at any time:

               (i)  the Company shall declare any dividend upon the Common Stock
payable  in  shares  of  stock  of any  class  or make  any  other  distribution
(including dividends or distributions  payable in cash out of retained earnings)
to the holders of the Common Stock;

               (ii) the  Company  shall offer for  subscription  pro rata to the
holders of the Common Stock any additional shares of stock of any class or other
rights;

               (iii) there shall be any capital reorganization  of the  Company,
or  reclassification  of the Common  Stock,  or  consolidation  or merger of the
Company with or into, or sale of all or substantially all its assets to, another
corporation or entity; or

               (iv) there  shall  be a  voluntary  or  involuntary  dissolution,
liquidation or winding-up of the Company;

then,  in each such case,  the Company  shall give to the holder of this Warrant
(a) notice of the date on which the books of the Company shall close or a record
shall be taken for  determining  the holders of Common Stock entitled to receive
any such dividend,  distribution,  or subscription rights or for determining the
holders of Common Stock entitled to vote in respect of any such  reorganization,
reclassification,  consolidation,  merger,  sale,  dissolution,  liquidation  or
winding-up  and (b) in the  case of any such  reorganization,  reclassification,
consolidation,  merger, sale, dissolution,  liquidation or winding-up, notice of
the date (or,  if not then  known,  a  reasonable  approximation  thereof by the
Company) when the same shall take place. Such notice shall also specify the date
on which the holders of Common Stock shall be entitled to receive such dividend,
distribution, or subscription rights or to exchange their Common Stock for stock
or  other  securities  or  property   deliverable   upon  such   reorganization,
reclassification,  consolidation,  merger, sale,  dissolution,  liquidation,  or
winding-up,  as the case  may be.  Such  notice  shall be given at least 30 days
prior to the record date or the date on which the Company's  books are closed in
respect thereto. Failure to give any such notice or any defect therein shall not
affect the validity of the proceedings  referred to in clauses (i), (ii),  (iii)
and (iv) above.

          (k)  CERTAIN EVENTS.  If any event occurs of the type  contemplated by
the adjustment  provisions of this Paragraph 4 but not expressly provided for by
such  provisions,  the  Company  will give  notice of such event as  provided in
Paragraph  4(g)  hereof,  and the  Company's  Board of  Directors  will  make an
appropriate  adjustment in the Exercise Price and the number of shares of Common

                                     Page 8
<PAGE>

Stock  acquirable upon exercise of this Warrant so that the rights of the Holder
shall be neither enhanced nor diminished by such event.

          (l)  CERTAIN DEFINITIONS.

               (i)  "COMMON STOCK DEEMED  OUTSTANDING"  shall mean the number of
shares of Common Stock  actually  outstanding  (not  including  shares of Common
Stock held in the  treasury of the  Company),  plus (x)  pursuant  to  Paragraph
4(b)(i) hereof, the maximum total number of shares of Common Stock issuable upon
the  exercise  of  Options,  as of the  date of such  issuance  or grant of such
Options,  if any,  and (y) pursuant to Paragraph  4(b)(ii)  hereof,  the maximum
total number of shares of Common Stock  issuable upon  conversion or exchange of
Convertible  Securities,  as  of  the  date  of  issuance  of  such  Convertible
Securities, if any.

               (ii) "MARKET PRICE," as of any date, (i) means the average of the
last reported sale prices for the shares of Common Stock on the Nasdaq  National
Market ("Nasdaq") for the five (5) trading days immediately  preceding such date
as reported by Bloomberg  Financial Markets or an equivalent  reliable reporting
service  mutually  acceptable to and hereafter  designated by the holder of this
Warrant and the Company  ("Bloomberg"),  or (ii) if Nasdaq is not the  principal
trading market for the shares of Common Stock,  the average of the last reported
sale prices on the principal trading market for the Common Stock during the same
period as reported by  Bloomberg,  or (iii) if market value cannot be calculated
as of such date on any of the  foregoing  bases,  the Market  Price shall be the
fair market  value as  reasonably  determined  in good faith by (a) the Board of
Directors of the Corporation or, at the option of a majority-in-interest  of the
holders of the outstanding  Warrants,  by (b) an independent  investment bank of
nationally  recognized  standing in the valuation of  businesses  similar to the
business of the  corporation.  The manner of determining the Market Price of the
Common Stock set forth in the foregoing  definition  shall apply with respect to
any other security in respect of which a  determination  as to market value must
be made hereunder.

               (iii)"COMMON  STOCK," for purposes of this  Paragraph 4, includes
the Common Stock,  par value $.001 per share,  and any additional class of stock
of the  Company  having  no  preference  as to  dividends  or  distributions  on
liquidation, provided that the shares purchasable pursuant to this Warrant shall
include only shares of Common  Stock,  par value $.001 per share,  in respect of
which this Warrant is exercisable,  or shares  resulting from any subdivision or
combination  of  such  Common  Stock,  or in the  case  of  any  reorganization,
reclassification, consolidation, merger, or sale of the character referred to in
Paragraph 4(e) hereof, the stock or other securities or property provided for in
such Paragraph.

     5.   ISSUE TAX. The issuance of  certificates  for Warrant  Shares upon the
exercise  of this  Warrant  shall be made  without  charge to the holder of this
Warrant or such shares for any issuance  tax or other costs in respect  thereof,

                                     Page 9
<PAGE>

provided  that the  Company  shall not be  required  to pay any tax which may be
payable in respect of any transfer  involved in the issuance and delivery of any
certificate in a name other than the holder of this Warrant.

     6.   NO RIGHTS OR  LIABILITIES  AS A  SHAREHOLDER.  This Warrant  shall not
entitle the holder  hereof to any voting rights or other rights as a shareholder
of the  Company.  No provision of this  Warrant,  in the absence of  affirmative
action by the holder hereof to purchase Warrant Shares,  and no mere enumeration
herein of the rights or privileges of the holder hereof,  shall give rise to any
liability  of such  holder for the  Exercise  Price or as a  shareholder  of the
Company,  whether  such  liability is asserted by the Company or by creditors of
the Company.

     7.   TRANSFER, EXCHANGE, AND REPLACEMENT OF WARRANT.

          (a)  RESTRICTION  ON TRANSFER.  This Warrant and the rights granted to
the holder hereof are transferable,  in whole or in part, upon surrender of this
Warrant,  together  with a properly  executed  assignment  in the form  attached
hereto,  at the office or agency of the Company  referred to in  Paragraph  7(e)
below,  provided,  however,  that any transfer or assignment shall be subject to
the  conditions set forth in Paragraph 7(f) hereof.  Until due  presentment  for
registration of transfer on the books of the Company,  the Company may treat the
registered  holder hereof as the owner and holder  hereof for all purposes,  and
the Company shall not be affected by any notice to the contrary.

          (b)  WARRANT EXCHANGEABLE FOR DIFFERENT DENOMINATIONS. This Warrant is
exchangeable,  upon the  surrender  hereof by the holder hereof at the office or
agency of the Company  referred to in Paragraph 7(e) below,  for new Warrants of
like tenor  representing  in the  aggregate  the right to purchase the number of
shares  of  Common  Stock  which may be  purchased  hereunder,  each of such new
Warrants to  represent  the right to purchase  such number of shares as shall be
designated by the holder hereof at the time of such surrender.

          (c)  REPLACEMENT  OF  WARRANT.  Upon  receipt of  evidence  reasonably
satisfactory to the Company of the loss,  theft,  destruction,  or mutilation of
this  Warrant and, in the case of any such loss,  theft,  or  destruction,  upon
delivery of an indemnity agreement reasonably satisfactory in form and amount to
the  Company,  or,  in the  case of any  such  mutilation,  upon  surrender  and
cancellation  of this  Warrant,  the Company,  at its expense,  will execute and
deliver, in lieu thereof, a new Warrant of like tenor.

          (d)  CANCELLATION;  PAYMENT OF  EXPENSES.  Upon the  surrender of this
Warrant in connection with any transfer, exchange, or replacement as provided in
this  Paragraph 7, this Warrant shall be promptly  canceled by the Company.  The
Company shall pay all taxes (other than securities transfer taxes) and all other
expenses  (other  than  legal  expenses,  if  any,  incurred  by the  Holder  or
transferees) and charges payable in connection with the preparation,  execution,
and delivery of Warrants pursuant to this Paragraph 7.

                                    Page 10
<PAGE>

          (e)  REGISTER.  The Company shall maintain, at its principal executive
offices (or such other  office or agency of the Company as it may  designate  by
notice to the holder hereof), a register for this Warrant,  in which the Company
shall  record the name and address of the person in whose name this  Warrant has
been issued,  as well as the name and address of each  transferee and each prior
owner of this Warrant.

          (f)  EXERCISE OR TRANSFER WITHOUT REGISTRATION. If, at the time of the
surrender of this Warrant in connection with any exercise, transfer, or exchange
of this  Warrant,  this  Warrant (or, in the case of any  exercise,  the Warrant
Shares issuable hereunder), shall not be registered under the Securities Act and
under  applicable  state securities or blue sky laws, the Company may require at
its expense,  as a condition of allowing such exercise,  transfer,  or exchange,
(i) that the holder or transferee of this Warrant,  as the case may be,  furnish
to the  Company a written  opinion of  counsel,  which  opinion  and counsel are
acceptable  to the  Company,  to the effect  that such  exercise,  transfer,  or
exchange may be made without  registration  under said Act and under  applicable
state  securities or blue sky laws,  (ii) that the holder or transferee  execute
and deliver to the Company an investment letter in form and substance acceptable
to the Company and (iii) that the  transferee  be an  "accredited  investor"  as
defined in Rule 501(a)  promulgated  under the Securities Act;  provided that no
such opinion,  letter or status as an "accredited investor" shall be required in
connection  with a transfer  pursuant to Rule 144 under the Securities  Act. The
first holder of this Warrant, by taking and holding the same,  represents to the
Company that such holder is acquiring this Warrant for investment and not with a
view to the distribution thereof.

     8.   REGISTRATION  RIGHTS.  The initial holder of this Warrant (and certain
assignees  thereof) is entitled  to the benefit of such  registration  rights in
respect of the Warrant  Shares as are set forth in the letter  agreement,  dated
September 8, 1999,  between the Company and the initial  holder of this Warrant.
The Company hereby covenants to include the Warrant Shares in each  Registration
Statement filed pursuant to the Stock Purchase  Agreement,  dated as of June 30,
2000, among the Company and each Investor listed therein (the "Stock and Warrant
Purchase Agreement"). In the event the initial holder transfers this Warrant, or
any portion thereof,  on one occasion to its employees following the Issue Date,
then the Company further covenants to promptly amend such Registration Statement
to include the resale of the Warrant  Shares by the new  holders  thereof.  Each
holder of this  Warrant  shall be entitled to the  benefits of Article IV of the
Stock and Warrant Purchase Agreement as if he were a party thereto.

     9.   NOTICES. All notices,  requests, and other communications  required or
permitted to be given or delivered hereunder to the holder of this Warrant shall
be in writing, and shall be personally delivered,  or shall be sent by certified
or registered mail or by recognized overnight mail courier,  postage prepaid and
addressed,  to such holder at the address  shown for such holder on the books of
the  Company,  or at such  other  address as shall  have been  furnished  to the
Company  by  notice  from  such  holder.  All  notices,   requests,   and  other
communications  required or permitted to be given or delivered  hereunder to the
Company shall be in writing, and shall be personally delivered, or shall be sent

                                    Page 11
<PAGE>

by certified or registered mail or by recognized overnight mail courier, postage
prepaid and  addressed,  to the office of the Company at 1520 East Pima  Street,
Phoenix,  Arizona 85034 Attention:  President and Chief Executive Officer, or at
such other address as shall have been furnished to the holder of this Warrant by
notice from the Company. Any such notice, request, or other communication may be
sent by facsimile, but shall in such case be subsequently confirmed by a writing
personally  delivered or sent by certified or  registered  mail or by recognized
overnight  mail  courier as provided  above.  All notices,  requests,  and other
communications  shall be  deemed to have  been  given  either at the time of the
receipt  thereof by the person entitled to receive such notice at the address of
such person for  purposes of this  Paragraph 9, or, if mailed by  registered  or
certified mail or with a recognized overnight mail courier upon deposit with the
United States Post Office or such overnight mail courier,  if postage is prepaid
and the mailing is properly addressed, as the case may be.

     10.  GOVERNING  LAW.  THIS  WARRANT  SHALL BE GOVERNED BY AND  CONSTRUED IN
ACCORDANCE WITH THE LAWS OF THE STATE OF DELAWARE  APPLICABLE TO AGREEMENTS MADE
AND TO BE PERFORMED IN THE STATE OF DELAWARE  (WITHOUT  REGARD TO  PRINCIPLES OF
CONFLICT OF LAWS). BOTH PARTIES  IRREVOCABLY  CONSENT TO THE JURISDICTION OF THE
UNITED  STATES  FEDERAL  COURTS AND THE STATE  COURTS  LOCATED IN DELAWARE  WITH
RESPECT TO ANY SUIT OR PROCEEDING BASED ON OR ARISING UNDER THIS AGREEMENT,  THE
AGREEMENTS ENTERED INTO IN CONNECTION HEREWITH OR THE TRANSACTIONS  CONTEMPLATED
HEREBY OR THEREBY AND IRREVOCABLY  AGREE THAT ALL CLAIMS IN RESPECT OF SUCH SUIT
OR PROCEEDING MAY BE DETERMINED IN SUCH COURTS.  BOTH PARTIES  IRREVOCABLY WAIVE
THE  DEFENSE  OF AN  INCONVENIENT  FORUM  TO THE  MAINTENANCE  OF  SUCH  SUIT OR
PROCEEDING.  BOTH  PARTIES  FURTHER  AGREE THAT  SERVICE OF PROCESS UPON A PARTY
MAILED BY FIRST CLASS MAIL SHALL BE DEEMED IN EVERY RESPECT EFFECTIVE SERVICE OF
PROCESS  UPON THE PARTY IN ANY SUCH SUIT OR  PROCEEDING.  NOTHING  HEREIN  SHALL
AFFECT EITHER  PARTY'S  RIGHT TO SERVE PROCESS IN ANY OTHER MANNER  PERMITTED BY
LAW. BOTH PARTIES AGREE THAT A FINAL NON-APPEALABLE JUDGMENT IN ANY SUCH SUIT OR
PROCEEDING  SHALL BE CONCLUSIVE  AND MAY BE ENFORCED IN OTHER  JURISDICTIONS  BY
SUIT ON SUCH JUDGMENT OR IN ANY OTHER LAWFUL MANNER.

     11.  MISCELLANEOUS.

          (a)  AMENDMENTS.  This  Warrant and any  provision  hereof may only be
amended by an instrument in writing signed by the Company and the holder hereof.

          (b)  DESCRIPTIVE  HEADINGS.  The  descriptive  headings of the several
paragraphs  of this Warrant are inserted  for  purposes of reference  only,  and
shall not affect the meaning or construction of any of the provisions hereof.

                                    Page 12
<PAGE>

          (c)  CASHLESS  EXERCISE.  Notwithstanding  anything  to  the  contrary
contained in this  Warrant,  this Warrant may be exercised by  presentation  and
surrender of this Warrant to the Company at its principal executive offices with
a written  notice of the  holder's  intention  to  effect a  cashless  exercise,
including  a  calculation  of the number of shares of Common  Stock to be issued
upon such exercise in accordance with the terms hereof (a "Cashless  Exercise").
In the event of a Cashless  Exercise,  in lieu of paying the  Exercise  Price in
cash,  the holder  shall  surrender  this  Warrant  for that number of shares of
Common Stock  determined by multiplying the number of Warrant Shares to which it
would  otherwise be entitled by a fraction,  the numerator of which shall be the
difference  between the then current  Market Price per share of the Common Stock
and the Exercise  Price,  and the denominator of which shall be the then current
Market Price per share of Common Stock.

                  [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

                                    Page 13
<PAGE>

     IN WITNESS WHEREOF, the Company has caused this Warrant to be signed by its
duly authorized officer.

                                           SKYMALL, INC.

                                           By: _________________________________
                                               Christine A. Aguilera
                                               General Manager, General Counsel
                                               and Secretary

Dated as of June 30, 2000

                                    Page 14
<PAGE>

                           FORM OF EXERCISE AGREEMENT

                                                      Dated:  ________ __, 200_

To: SkyMall, Inc.

     The  undersigned,  pursuant  to the  provisions  set  forth  in the  within
Warrant,  hereby agrees to purchase  ________  shares of Common Stock covered by
such Warrant, and makes payment herewith in full therefor at the price per share
provided by such Warrant in cash or by  certified or official  bank check in the
amount of,  or, if the resale of such  Common  Stock by the  undersigned  is not
currently registered pursuant to an effective  registration  statement under the
Securities  Act of 1933, as amended,  by surrender of  securities  issued by the
Company  (including a portion of the Warrant) having a market value (in the case
of a portion of this Warrant, determined in accordance with Section 11(c) of the
Warrant) equal to $_________.  Please issue a certificate  or  certificates  for
such shares of Common  Stock in the name of and pay any cash for any  fractional
share to:

                                   Name:  ______________________________________

                                   Signature: __________________________________

                                   Address:  ___________________________________

                                             ___________________________________

                                   Note: The above  signature should  correspond
                                   exactly  with  the  name on the  face of  the
                                   within Warrant.

and,  if said  number  of shares of  Common  Stock  shall not be all the  shares
purchasable under the within Warrant,  a new Warrant is to be issued in the name
of said undersigned  covering the balance of the shares  purchasable  thereunder
less any fraction of a share paid in cash.

                                    Page 15
<PAGE>

                               FORM OF ASSIGNMENT

     FOR VALUE RECEIVED,  the undersigned hereby sells,  assigns,  and transfers
all the rights of the undersigned under the within Warrant,  with respect to the
number of shares of Common Stock covered thereby set forth hereinbelow, to:

NAME OF ASSIGNEE                    ADDRESS                         NO OF SHARES

, and hereby irrevocably  constitutes and appoints  ____________________________
as agent and  attorney-in-fact  to  transfer  said  Warrant  on the books of the
within-named corporation, with full power of substitution in the premises.

Dated:  ________ __, 200_

In the presence of:

__________________________

                                   Name:  ______________________________________

                                   Signature: __________________________________

                                   Title of Signing Officer or Agent (if any):

                                   _____________________________________________

                                   Address:  ___________________________________

                                             ___________________________________

                                   Note: The above  signature should  correspond
                                   exactly  with  the  name on the  face of  the
                                   within Warrant.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00012-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00012-of-00352.parquet"}]]